Rapid aspiration thrombectomy system and method

Information

  • Patent Grant
  • 11633571
  • Patent Number
    11,633,571
  • Date Filed
    Tuesday, March 17, 2020
    4 years ago
  • Date Issued
    Tuesday, April 25, 2023
    a year ago
Abstract
An intravascular access system for facilitation of intraluminal medical procedures within the neurovasculature through an access sheath. The system includes an aspiration or support catheter having a flexible, distal luminal portion having an inner diameter defining a lumen extending between a proximal opening at a proximal end of the luminal portion and a distal opening at a distal end of the luminal portion. The catheter has a rigid spine coupled to at least the proximal end of the luminal portion and extending proximally therefrom. The system includes a dilator having a flexible, distal dilator portion sized to be received within the lumen of the luminal portion. Associated systems, devices, and methods of use are also described.
Description
BACKGROUND

The present disclosure relates generally to medical methods and devices for the treatment of acute ischemic stroke. More particularly, the present disclosure relates to methods and systems for navigating complex anatomy to perform rapid and safe aspiration and removal of cerebral occlusions.


Acute ischemic stroke is the sudden blockage of adequate blood flow to a section of the brain, usually caused by thrombus or other emboli lodging or forming in one of the blood vessels supplying the brain. If this blockage is not quickly resolved, the ischemia may lead to permanent neurologic deficit or death. The timeframe for effective treatment of stroke is within 3 hours for intravenous (IV) thrombolytic therapy and 6 hours for site-directed intra-arterial thrombolytic therapy or up to 8 hours for interventional recanalization of a blocked cerebral artery. Re-perfusing the ischemic brain after this time period has no overall benefit to the patient, and may in fact cause harm due to the increased risk of intracranial hemorrhage from fibrinolytic use. Even within this time period, there is strong evidence that the shorter the time period between onset of symptoms and treatment, the better the results. Unfortunately, the ability to recognize symptoms, deliver patients to stroke treatment sites, and finally to treat these patients within this timeframe is rare. Despite treatment advances, stroke remains the third leading cause of death and the leading cause of serious, long-term disability in the United States.


Endovascular treatment of acute stroke is comprised of either the intra-arterial administration of thrombolytic drugs such as recombinant tissue plasminogen activator (rtPA), mechanical removal of the blockage, or a combination of the two. As mentioned above, these interventional treatments must occur within hours of the onset of symptoms. Both intra-arterial (IA) thrombolytic therapy and interventional thrombectomy involve accessing the blocked cerebral artery via endovascular techniques and devices.


Like IV thrombolytic therapy, IA thrombolytic therapy alone has the limitation in that it may take several hours of infusion to effectively dissolve the clot. Interventional thrombectomy therapies have involved capturing and removing the clot using snares, coils or temporary stents (also known as retrievable stent devices), and suctioning the clot with or without adjunct disruption of the clot. Retrievable stent devices are also utilized to restore flow quickly to the vessel during the intervention. Hybrid procedures are also utilized, combining retrievable stent devices and aspiration via the guide catheter or via intermediate catheters to aid in the removal of the clot and reduce the risk of distal emboli. Finally, balloons or stents have been used to create a patent lumen through the clot when clot removal or dissolution was not possible.


To access the cerebral anatomy, guide catheters or guide sheaths are used to guide interventional devices to the target anatomy from an arterial access site, typically the femoral artery. Balloon guide catheters are often used to enable proximal carotid artery occlusion during periods of the procedure which may potentially liberate a high level of emboli. The proximal occlusion has the effect of arresting forward flow and increasing aspiration efficiency through the lumen of the guide catheter. The length of the guide is determined by the distance between the access site and the desired location of the guide distal tip. Interventional devices such as guidewires, microcatheters, and intermediate catheters used for sub-selective guides and aspiration, are inserted through the guide and advanced to the target site. Often, devices are used in a co-axial fashion, namely, a guidewire inside a microcatheter inside an intermediate catheter is advanced as an assembly to the target site in a stepwise fashion with the inner, most atraumatic elements, advancing distally first and providing support for advancement of the outer elements. The length of each element of the coaxial assemblage takes into account the length of the guide, the length of proximal connectors on the catheters, and the length needed to extend from the distal end. Thus, for example, the working length of an intermediate catheter is typically 20-40 cm longer than the working length of a guide, and the working length of a microcatheter is typically 10-30 cm longer than the working length of the intermediate catheter. The guidewire is typically longer than the microcatheter by another 20-50 cm.


Some exemplary issues with current technology include the time required or even the ability to access the site of the occlusion, the time required to restore flow or the inability to fully, or even partially, restore flow to the vessel, the occurrence of distal emboli during the procedure, which has potentially negative neurologic effect and procedural complications such as perforation and intracerebral hemorrhage. There is a need for a system of devices and methods that enable rapid access, optimized aspiration of the clot, distal protection throughout all stages of the procedure, which potentially liberate emboli, and safe and rapid exchange of devices as needed to fully restore flow to the blocked cerebral vessel.


SUMMARY

In one aspect, there is disclosed an intravascular access system for facilitation of intraluminal medical procedures within the neurovasculature through an access sheath. The system includes an aspiration or support catheter having a flexible, distal luminal portion having an inner diameter defining a lumen extending between a proximal opening at a proximal end of the luminal portion and a distal opening at a distal end of the luminal portion. The catheter has a rigid spine coupled to at least the proximal end of the luminal portion and extending proximally therefrom. The system includes a dilator having a flexible, distal dilator portion sized to be received within the lumen of the luminal portion; and a rigid, dilator spine extending proximally from the dilator portion.


The dilator spine can align side-by-side with the spine of the catheter. The distal dilator portion can have a tapered distal tip. The dilator can have a length at least as long as a length of the catheter such that a distal tip of the dilator protrudes from the distal opening of the luminal portion. The dilator can be generally tubular along at least a portion of the length. A proximal end of the catheter spine can include a gripping feature configured for a user to grasp in order to move the catheter through an access sheath. A proximal end of the dilator spine can include a tab configured to be locked with the gripping feature on the catheter spine. When the catheter and the dilator are in a locked configuration they can be advanced as a single unit through the access sheath. The gripping feature and the dilator tab can be removably coupled such that in a locked configuration the dilator tab engages the gripping feature and in an unlocked configuration the dilator tab disengages from the gripping feature. The dilator tab can be affixed to the dilator or can be slidable on the dilator to accommodate different relative positions between the dilator and the catheter. The distal dilator portion can include one or more detents on an outer surface configured to lock with correspondingly-shaped surface features on an inner surface of the luminal portion lumen through which the dilator portion extends. The dilator spine and the catheter spine can have a similar stiffness and kink-resistance. The dilator can have a visual marker on a distal end and/or a proximal end of the distal tip. A distal end region of the dilator can be more flexible and increasingly stiffen towards a proximal end region of the dilator. The catheter spine and dilator spine can be configured to cause bi-directional sliding movement of the luminal portion through a lumen of an access sheath and navigate the luminal portion into a cerebral vessel to reach a treatment site.


In an interrelated aspect, disclosed is an intravascular access system for facilitation of intraluminal medical procedures within the neurovasculature having an access sheath and an aspiration or support catheter. The access sheath has a sheath body having an inner diameter defining a lumen between a proximal end and a distal end of the sheath body. The sheath body has at least one opening from the lumen near a distal end region of the sheath body. The aspiration or support catheter includes a flexible, distal luminal portion having an outer diameter sized for insertion through the lumen of the access sheath, an inner diameter defining a lumen extending between a proximal opening at a proximal end of the luminal portion and a distal opening at a distal end of the luminal portion, and a length between the proximal opening and the distal opening. The aspiration or support catheter includes a rigid spine coupled to at least the proximal end of the luminal portion and extending proximally therefrom. The rigid spine is configured to cause bi-directional sliding movement of the luminal portion through the lumen of the access sheath and out the at least one opening to navigate the luminal portion into a cerebral vessel to reach a treatment site. A portion of the outer diameter of the luminal portion fluidly seals with the inner diameter of the access sheath when the distal end of the luminal portion extends into the cerebral vessel to reach the treatment site.


The luminal portion and the sheath body can be concentrically aligned and the lumen of the luminal portion and the lumen of the sheath body form a contiguous aspiration lumen from the distal end of the luminal portion to the proximal end of the sheath body. The contiguous aspiration lumen can be used to aspirate fluid and debris from the distal opening of the luminal portion. The contiguous aspiration lumen can be to deliver materials through the distal opening of the luminal portion. The contiguous aspiration lumen can form a step-up in diameter where the lumen of the luminal portion empties into the lumen of the sheath body. The lumen of the luminal portion can be shorter than the lumen of the sheath body. The luminal portion and the sheath body can form an overlap region when the luminal portion extends distally beyond the at least one opening of the sheath body. The outer diameter of the luminal portion can approach the inner diameter of the lumen of the sheath body such that a seal is formed by the overlap region. The seal can be configured to enable sealing against a vacuum of up to 25 inHg, or up to 28 inHg. The seal within the overlap region can be configured to enable sealing against a pressure of up to 300 mmHg or up to 600 or up to 700 mmHg. The seal can be located distal a proximal end of the luminal portion and proximal to the at least one opening of the sheath body.


The system can further include a sealing element positioned on an external surface of the luminal portion. The sealing element can include a stepped up diameter or protruding feature in the overlap region. The sealing element can include one or more external ridge features. The one or more ridge features can be compressible when the luminal portion is inserted into the lumen of the sheath body. The sealing element can include one or more inclined surfaces biased against an inner surface of the sheath body lumen. The sealing element can include one or more expandable members actuated to seal. The sheath body can have an outer diameter suitable for insertion into the carotid artery. The outer diameter of the sheath body can be between 5 Fr and 7 Fr.


The sheath body can have a length between the proximal end and the distal end suitable for locating the distal end of the sheath body at the petrous portion of an internal carotid artery from a transfemoral approach. The length of the sheath body can be between 80 cm and 105 cm. The length of the luminal portion can be between 10 cm and 25 cm. The length of the luminal portion can be less than a length of the sheath body such that as the catheter is retracted into the sheath body a seal remains between an overlap region of the luminal portion and the inner diameter of the sheath body.


The spine can be longer than an entire length of the sheath body. The luminal portion can include three or more layers including an inner lubricious liner, a reinforcement layer, and an outer jacket layer. The outer jacket layer can be composed of discreet sections of polymer with different durometers, compositions, and/or thicknesses to vary the flexibility along the length of the distal luminal portion. The outer diameter of the distal luminal portion can be sized for navigation into cerebral arteries. The inner diameter of the distal luminal portion can be between 0.040″ and 0.088″. The outer diameter of the luminal portion can approach the inner diameter of the sheath body creating a sealed area at an overlap region while still allowing the catheter to move through the sheath body. The catheter can be tapered towards the distal opening such that a distal-most end of the luminal portion has a smaller outer diameter compared to a more proximal region of the luminal portion near where the luminal portion seals with the sheath body. The distal end region of the sheath body can include an occlusion element. The distal end region of the sheath body can include an expanding distal tip. The at least one opening from the lumen can include a side opening located a distance away from a distal tip of the sheath body. The distal tip of the sheath body further can include a ramp feature configured to direct at an angulation the catheter away from a longitudinal axis of the sheath body lumen out through the at least one opening.


The spine can be longer than an entire length of the sheath body. The spine can be a wire having an outer dimension from 0.014″ to 0.018″. The spine can be a hypotube having a guide-wire passageway extending therethrough. The spine can be a ribbon having an outer dimension from 0.010″ to 0.025″ thick. The ribbon can be curved along at least a portion of an arc. The spine can be configured to rotate the luminal portion around a longitudinal axis of the access sheath. The spine can be eccentrically coupled to the luminal portion and the spine extend proximally from the luminal portion to outside the proximal end of the sheath body. The proximal end of the luminal portion can have an angled cut. The angled cut can be generally planar or curved. The sheath body can have one or more visual markers on the distal end region of the sheath body. The distal luminal portion can have one or more visual markers at a distal end region of the luminal portion, a proximal end region of the luminal portion or both. The one or more visual markers on the sheath body and the one or more visual markers on the luminal portion can be visually distinct. The spine can have one or more visual markers. The one or more visual markers of the spine can indicate overlap between the distal luminal portion and the sheath body. The one or more visual markers of the spine can be positioned so that when the visual marker of the spine is aligned with a portion of the access sheath, the catheter is positioned at a distal-most position with minimal overlap length needed to create a seal between the catheter and the sheath body.


The system can further include a dilator having a flexible, distal dilator portion having a distal tip and sized to be received within the luminal portion of the catheter. The dilator can be a tubular element along at least a portion of its length. The dilator can be a solid rod formed of malleable material configured to be shaped by a user. The dilator can further include a rigid, dilator spine extending proximally from the dilator portion. The dilator spine can be coaxial and can have a lumen extending through it. The dilator spine can be eccentric. When in use, the dilator spine can align side-by-side with the spine of the catheter. The distal tip of the dilator can be tapered. The dilator can have a length at least as long as a length of the catheter such that the distal tip protrudes from the distal opening of the luminal portion. A proximal end of the spine can include a gripping feature configured for a user to grasp in order to move the catheter through the access sheath. A proximal end of the dilator spine can include a tab configured to be locked with the gripping feature on the catheter spine. When the catheter and dilator are in a locked configuration they can be advanced as a single unit through the sheath body. The gripping feature and the dilator tab can be removably coupled such that in a locked configuration the dilator tab engages the gripping feature and in an unlocked configuration the dilator tab disengages from the gripping feature. The dilator tab can be affixed to the dilator and/or can be slidable on the dilator to accommodate different relative positions between the dilator and the catheter.


The distal dilator portion can include one or more detents on an outer surface configured to lock with correspondingly-shaped surface features on an inner surface of the luminal portion lumen through which the dilator portion extends. The dilator spine and the catheter spine can have a similar stiffness and kink-resistance. The dilator can have a visual marker on a distal end and/or a proximal end of the distal tip. A distal end region of the dilator can be more flexible and increasingly stiffens towards the proximal end region of the dilator.


The access sheath can further include a connector that connects the proximal end of the sheath body to a proximal hemostasis valve. The proximal hemostasis valve can have an adjustable opening sized large enough to allow removal of the catheter without dislodging any clots thereon. When in use with the access sheath, the rigid spine of the catheter can extend proximally from the luminal portion through the access sheath lumen and out the proximal hemostasis valve of the access sheath. The connector can provide a connection of the proximal end of the sheath body to an aspiration line. The connector can have a large bore inner lumen and connects to a large-bore aspiration line. The aspiration line can connect to an aspiration source. The aspiration source can be an active aspiration source. The aspiration line can connect to a forward drip or flush line. The access sheath can further include a proximal extension portion such that when the distal luminal portion of the catheter is withdrawn from the sheath body lumen it remains within the proximal extension portion. The inner diameter of the luminal portion can be sized to permit placement of an interventional device through the luminal portion.


Other features and advantages should be apparent from the following description of various implementations, which illustrate, by way of example, the principles of the invention.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an exploded view of a system of devices for accessing and removing a cerebral occlusion to treat acute ischemic stroke from a femoral artery access site;



FIG. 2A shows components of the system of FIG. 1 in position in a patient from the transfemoral approach to treat the occlusion;



FIG. 2B is a detailed view of a portion of the system of FIG. 2A taken along circle BB;



FIG. 3 shows components of the system of FIG. 1 being used via a transcarotid access site;



FIG. 4 shows an implementation of an access sheath;



FIG. 5 shows an implementation of a proximal portion of the access sheath of FIG. 4 provided as a separate, removable component;



FIG. 6 shows an implementation of a connector to minimize flow resistance through the access sheath of FIG. 4 into the proximal portion;



FIG. 7 shows an implementation of an access sheath having an occlusion balloon;



FIGS. 8A-8B show implementations of sealing elements between the access sheath body and luminal portion of a catheter extending therethrough;



FIG. 9 shows an implementation of a microcatheter and retrievable stent device positioned through a spined catheter;



FIGS. 10A-10C show implementations of expandable portions on retrievable stent devices;



FIG. 11 shows an implementation of an aspiration system for use with the systems described herein;



FIG. 12A shows an implementation of a spined catheter system for use with the systems described herein;



FIG. 12B shows the spined catheter system of FIG. 12A having a spined dilator extending through a lumen of a spined catheter;



FIG. 12C shows the spined catheter system of FIG. 12A extended through a side opening of an implementation of an access sheath;



FIG. 13 is a cross-sectional view taken about line A-A of FIG. 12B;



FIG. 14 is a cross-sectional view taken about line B-B of FIG. 12B;



FIG. 15A shows an implementation of a spined aspiration catheter-dilator system having a spined catheter and a spined dilator in a locked configuration;



FIG. 15B shows the spined aspiration catheter-dilator system having the spined catheter and the spined dilator in an unlocked configuration;



FIG. 16 shows an implementation of a spined catheter system extending distally to an access sheath to treat an embolus in a cerebral vessel.





DETAILED DESCRIPTION

One of the major drawbacks to current acute stroke intervention procedures is the amount of time required to restore blood perfusion to the brain. This time includes the time it takes to access the occlusive site or sites in the cerebral artery, and the time it takes to completely remove the occlusion in the artery. Because it is often the case that more than one attempt must be made to completely remove the occlusion, reducing the number of attempts as well as reducing the time required to exchange devices for additional attempts is an important factor in minimizing the overall time. Additionally, each attempt is associated with potential procedural risk due to device advancement in the delicate cerebral vasculature.


Disclosed herein are methods and devices that enable safe and rapid access to the complex neurovascular anatomies of the cerebral and intracranial arteries and removal of the occlusion. The methods and devices include one or more access devices, catheters, and thrombectomy devices to remove the occlusion. Methods and devices are also disclosed to provide active aspiration and/or passive flow reversal for the purpose of facilitating removal of the occlusion as well as minimizing distal emboli. The system offers the user a degree of flow control so as to address the specific hemodynamic requirements of the cerebral vasculature. The systems described herein provide superior ease of use in that a single operator may operate the disclosed systems using single-point continuous aspiration for rapid and safe exchange without switching. The higher efficiency of aspiration force through the systems described herein reduces distal embolic debris and increases the rate of “one-pass” thrombectomy.


It should be appreciated that while some embodiments are described with specific regard to aspirating a neurovascular anatomy, the embodiments are not so limited and may also be applicable to other uses. For example, the spined aspiration catheter and one or more components of the access systems described herein may be used to deliver working devices to a target vessel of a coronary anatomy, or other vasculature anatomy. It should be appreciated that where the phrase “aspiration catheter” is used herein that such a catheter may be used for other purposes besides or in addition to aspiration, such as the delivery of fluids to a treatment site or as a support catheter providing a conduit that facilitates and guides the delivery or exchange of other devices such as a guidewire or interventional devices. Alternatively, the access systems need not be limited only to the vasculature can be useful for access of other parts of the body outside the vasculature. It should also be appreciated that reference throughout this specification to a particular feature, structure, configuration, characteristic or implementation or embodiment may be combined in any suitable manner. The use of relative terms throughout the description may denote a relative position or direction. For example, “distal” may indicate a first direction away from a reference point. Similarly, “proximal” may indicate a location in a second direction opposite to the first direction. However, such terms are provided to establish relative frames of reference, and are not intended to limit the use or orientation of an anchoring delivery system to a specific configuration described in the various embodiments below.



FIG. 1 shows a system of devices for accessing and removing a cerebral occlusion to treat acute ischemic stroke from a femoral artery access site. The system 100 includes an access sheath 220, sheath dilator 250, guidewire 270, one or more spined aspiration or support catheters 320, dilator 340, microcatheter 400, and a retrievable stent device 500, each of which will be described in more detail below. Further, the system 100 can include one or more arterial access sheath system 200 that includes an access sheath 220, one or more sheath dilators 250 and a sheath guidewire 270. The system 100 can include one or more spined catheter systems 300 including a spined aspiration or support catheter 320, a tapered dilator 340, and alternatively a catheter clearing tool 350. The spine catheter system 300 can incorporate nested spined catheters to provide for extended reach into distal sites. The system 100 can include an access sheath system 200, a tapered catheter system 300, a microcatheter 400, and a retrievable stent device 500.



FIG. 2A shows some elements of the system in position in the patient from the transfemoral approach to treat the occlusion. The access sheath 220 can be inserted through a femoral artery insertion site positioned with the distal tip of the access sheath 220 at or near the petrous portion of the internal carotid artery ICA. The spined aspiration catheter 320 can be positioned with the distal tip at the face of the occlusion in the artery. In some implementations, the access sheath 220 can be inserted through a direct puncture in the wall of the common carotid artery and advanced into the internal carotid artery rather than via a transfemoral approach (see FIG. 3).


As seen more clearly in detailed FIG. 2B, the access sheath 220 can have a sheath body 222 and an inner lumen 223 extending between a proximal end and a distal end region of the sheath body 222. The spined aspiration catheter 320 is sized to extend through the inner lumen 223 of the access sheath 220 such that a distal end region of the catheter 320 extends beyond a distal end region of the access sheath 220. The catheter 320 is shown in FIG. 2B exiting the lumen 223 of the sheath body 222 through a distal opening 221. It should be appreciated, however, that the sheath body 222 may have one or more side openings near a distal end region of the body 222 through which the catheter 320 can extend (see FIG. 12C) as will be described in more detail below.


Still with respect to FIG. 2B, the spined aspiration catheter 320 can include a relatively flexible, distal luminal portion 322 coupled to a stiff and kink-resistant proximal spine 330. The distal luminal portion 322 can have an inner lumen 323 extending between a proximal end and a distal end of the luminal portion 322. The lumen 323 of the catheter 320 can have a first inner diameter and the lumen 223 of the access sheath 220 can have a second, larger inner diameter. The lumens 223, 323 are fluidly connected and contiguous such that fluid flow into and/or out of the system is possible, such as by applying suction from an aspiration source coupled to the system via a connector 226 on the access sheath 220. An overlap region 120 between the distal section of the sheath body 222 and the luminal portion 322 of the catheter 320 is sized and configured to create a seal that enables a continuous aspiration lumen from the distal tip region of the spined catheter 320 to the proximal sheath connector 226. If the sheath body 222 has a side opening through which the distal luminal portion 322 of the catheter 320 extends, the seal created at the overlap region 120 between the sheath body 222 and the luminal portion 322 is located proximal to the side opening.


Key dimensions that affect aspiration force through a tube include radius (r), pressure (P), viscosity (n) and length (L) where Flow=Q=πr4(ΔP)/8 nL. Changes in radius increase flow to the 4th power and length is inversely proportional to flow. As will be described in more detail below, the aspiration catheter has an over-the-wire portion that is a fraction of the overall distance required to reach the target site. This configuration greatly speeds up the time required to retract and re-advance the catheter. Further, the systems described herein can provide for a markedly increased radius and luminal area for aspiration of the clot and markedly shorter length, particularly compared to prior systems where the aspiration lumen runs along the entire inner diameter of the aspiration catheter. In the systems described herein, the majority of the aspiration lumen has a radius of the procedural sheath. The catheter 320 is smaller in diameter than the guide, but steps up in luminal diameter upon reaching the lumen of the access sheath 220 allowing for a greater aspiration force to be applied to a majority of the length of the luminal system. Further, the overall length of this narrow diameter region of the catheter 320 is much shorter compared to the overall length of the access sheath. The proximal spine 330 of the catheter 320 has a length and structure that extends through the lumen 223 of the access sheath 220 to a proximal end of the system such that it can be used to advance and retract the catheter 320 through the lumen 223 of the sheath 220. The spine 330 of the aspiration catheter 320, however, takes up only a fraction of the luminal space the system resulting in increased luminal area for aspiration. Increased luminal area for aspiration increases the time it takes to aspirate the occlusion and increases the possibility of removing the occlusion in a single aspiration attempt. The stepped up luminal diameter also increases the annular area available for forward flushing of contrast, saline, or other solutions while devices such as microcatheters or tapered dilators are coaxially positioned in the spined catheter 320 and access sheath 220. This can increase the ease and ability to perform angiograms during device navigation.


Current stroke interventions pose a risk of distal emboli being released. During the effort to remove or dissolve clot blockages in the cerebral artery, for example, there is a significant risk of thrombus fragmentation creating embolic particles that can migrate downstream into either the occluded vessel or other vessels and compromise cerebral perfusion. In carotid artery stenting procedures (CAS), embolic protection devices and systems are commonly used to reduce the risk of embolic material from entering the cerebral vasculature. The types of devices include intravascular distal filters, and reverse flow or static flow systems. Unfortunately, because of the delicate anatomy and access challenges as well as the need for rapid intervention, these types of embolic protection systems are not used in interventional treatment of acute ischemic stroke. The period of a stroke intervention when flow is restored is normally considered an important time as the brain is now being perfused by blood. However, it is also a period of embolic risk. While there is blockage in the artery, there is no flow. Therefore any embolic debris created by crossing the occlusion with guidewire and/or microcatheter, or deployment of a retrievable stent device across the occlusion, remains stagnant. However, when flow is restored to the artery, the emboli can now flow antegrade to distal vascular territories.


A second period of embolic risk occurs when the retrievable stent device is being pulled back into the guide or catheter. In prior methods and devices, aspiration is applied to the intermediate catheter during retrievable stent device retraction into the catheter, or the catheter and retrievable stent device are pulled back together into the guide, while simultaneously applying aspiration to the guide catheter. Two points of aspiration, through the catheter and through the guide, may both be utilized to reduce risk of distal emboli during the critical step of drawing the occlusion through the guide and out of the patient. Often, two people are required to enable two points of aspiration, or aspiration is performed sequentially from first the catheter and then the guide, which may lead to interruption in aspiration or sub-optimal aspiration. In the disclosed systems and methods, reverse flow may be applied to the target site during device advancement, at the critical time of flow restoration, and during the entire time that the occlusion is being removed, with a single point of aspiration.


In an aspect of the disclosure, the level of aspiration may be modified from a low level to achieve adequate protection from distal emboli, to a higher level to provide effective aspiration removal of the occlusion. This aspect allows distal protection without high levels of blood loss, yet allows a strong aspiration force as needed to remove the occlusion.


In another aspect, there are disclosed methods and devices for additionally providing active aspiration or passive retrograde flow during the procedure to remove thrombus and to minimize distal emboli. The system offers the user a degree of blood flow control so as to address the specific hemodynamic requirements of the cerebral vasculature. The system may include a flow controller, which allows the user to control the timing and mode of aspiration.


In another aspect, there are disclosed methods and devices for additionally providing flushing steps to minimize emboli entrapment in the system and increased visibility of particulates in the system during use.


The following descriptions provide detailed implementations and benefits of each aspect of the disclosed invention.


Referring again to FIG. 1 illustrating an implementation of an access sheath 220. The sheath 220 can include a sheath body 222 that is the insertable portion of the sheath 220 (i.e. the portion that inserts into the patient), a proximal connector 226, an aspiration line 230, a proximal hemostasis valve 234 and a flush line 236. The sheath 220 may also include a proximal extension portion 240, and may also include a valve on the connector 226 to fluidly isolate the sheath body 222 from the proximal portion 240 of the access sheath 220. The access sheath 220 may come in a kit with one or more dilators 250, and a sheath guidewire 270.


The diameter of the sheath body 222 is suitable for insertion into the carotid artery, with an inner lumen 223 that is suitably sized for providing a passageway for catheters to treat the occlusion. In an implementation, the sheath body 222 can have an inner diameter of about 0.074″ and an outer diameter of about 0.090″, corresponding to a 5 French sheath size, an inner diameter of about 0.087″ and an outer diameter of about 0.104″, corresponding to a 6 French sheath size, or an inner diameter of about 0.100″ and an outer diameter of about 0.177″, corresponding to a 7 French sheath size. The length of the sheath body 222 is configured to enable the distal tip of the sheath body 222 to be positioned as far distal as the petrous portion of the internal carotid artery. In an implementation, the sheath body 222 length is suitable for a transfemoral approach, in the range 80 to 90 cm or up to about 100 cm or up to about 105 cm. In an implementation, the sheath body 222 length is suitable for a transcarotid approach to the petrous ICA, in the range 20 to 25 cm. In an implementation, the sheath body 222 length is suitable for a transcarotid approach to the CCA or proximal ICA, in the range 10-15 cm. The sheath body 222 is configured to assume and navigate the bends of the vasculature and be subject to high aspiration forces without kinking, collapsing, or causing vascular trauma.


The sheath body 222 can be constructed in two or more layers. An inner liner can be constructed from a low friction polymer such as PTFE (polytetrafluoroethylene) or FEP (fluorinated ethylene propylene) to provide a smooth surface for the advancement of devices through the inner lumen. An outer jacket material can provide mechanical integrity to the inner liner and may be constructed from materials such as PEBAX, thermoplastic polyurethane, polyethylene, nylon, or the like. A third layer can be incorporated that can provide reinforcement between the inner liner and the outer jacket. The reinforcement layer can prevent flattening or kinking of the inner lumen of the sheath body 222 to allow unimpeded device navigation through bends in the vasculature as well as aspiration or reverse flow. The sheath body 222 can be circumferentially reinforced. The reinforcement layer can be made from metal such as stainless steel, Nitinol, Nitinol braid, helical ribbon, helical wire, cut stainless steel, or the like, or stiff polymer such as PEEK. The reinforcement layer can be a structure such as a coil or braid, or tubing that has been laser-cut or machine-cut so as to be flexible. In another implementation, the reinforcement layer can be a cut hypotube such as a Nitinol hypotube or cut rigid polymer, or the like.


The flexibility of the sheath body 222 can vary over its length, with increasing flexibility towards the distal portion of the sheath body 222. The variability in flexibility may be achieved in various ways. For example, the outer jacket may change in durometer and/or material at various sections. A lower durometer outer jacket material can be used in a distal section of the sheath compared to other sections of the sheath. Alternately, the wall thickness of the jacket material may be reduced, and/or the density of the reinforcement layer may be varied to increase the flexibility. For example, the pitch of the coil or braid may be stretched out, or the cut pattern in the tubing may be varied to be more flexible. Alternately, the reinforcement structure or the materials may change over the length of the sheath body 222. In an implementation, the distal-most section has a flexural stiffness (E*I) in the range 50 to 300 N-mm2 and the remaining portion of the sheath body 222 has a flexural stiffness in the range 500 to 1500 N-mm2, where E is the elastic modulus and I is the area moment of inertia of the device. In another implementation, there is a transition section between the distal-most flexible section and the proximal section, with one or more sections of varying flexibilities between the distal-most section and the remainder of the sheath body 222. In this implementation, the distal-most section is about 2 cm to about 5 cm, the transition section is about 2 cm to about 10 cm and the proximal section takes up the remainder of the sheath length.


The tip of the sheath body 222 may include one or more distal radiopaque markers 224 (see FIG. 1). In an implementation, the radiopaque tip marker 224 is a metal band, for example platinum iridium alloy, embedded near the distal end of the sheath body 222. Alternately, the access sheath tip material may be a separate radiopaque material, for example a barium polymer or tungsten polymer blend. The distal region of the sheath body 222 is also the area of the overlap region 120 that allows a seal between the catheter 320 and the sheath body 222, creating a continuous aspiration lumen. Thus, the outer diameter of the luminal portion 322 of the aspiration catheter 320 approaches the inner diameter of the distal region of the sheath body 222 lumen 223 such that a seal is formed. The relative location of the seal formed may vary depending on where the aspiration catheter 320 exits the lumen 223 of the sheath body 222 and the location of the openings from the sheath body 222, as described in more detail below. For example, if the sheath body 222 has an opening at the distal tip the location of the seal may be closer to the distal end of the sheath body 222 compared to if the sheath body 222 has one or more side openings in the distal end region of the sheath body 222 through which the catheter 320 exits the lumen 223.


Referring again to FIG. 1, the access sheath 220 also can include a connector 226 that connects a proximal end of the sheath body 222 to the proximal hemostasis valve 234, and also provides a connection to the aspiration line 230. This connector 226 can have a large bore inner lumen, and connects to a large-bore aspiration line 230. In an implementation, the inner lumen of the connector 226 is at least 0.080″. In an implementation, the inner lumen of the aspiration line 230 is at least 0.080″. The aspiration line 230 can terminate in a stopcock, female Luer connector, or other connector 232 that allows connection to an aspiration source. In an implementation, the aspiration source is an active aspiration source such as a syringe or a pump. In another implementation, the aspiration source is a reverse flow shunt line such as that described in U.S. Pat. No. 8,157,760 and US Patent Publication Number 2010/0217276, which are both incorporated by reference. The large bore aspiration line 230 can be constructed to be resistant to collapse. For example, the aspiration line 230 can be a thick-walled polymer tubing or a reinforced polymer tubing. The aspiration line valve 232 enables the line 230 to be opened or closed. In one implementation, the valve 232 also allows connection of one or more additional fluid lines, for connecting a forward drip or a flush line for contrast or saline injections. As an example, the valve 232 may be a stopcock manifold commonly used in interventional procedures to allow multiple connections. The connector 226 may also include means to secure the access sheath 220 to the patient to reduce the risk of sheath dislodgement during the case. For example, the connector 226 may include one or more suture eyelets 233.


With reference still to FIG. 1, the proximal end of the access sheath 220 can terminate in a proximal hemostasis valve 234. This valve 234 allows the introduction of devices through the sheath 220 into the vasculature, while preventing or minimizing blood loss and preventing air introduction into the access sheath 220. The hemostasis valve 234 can include a flush line 236 or a connection to a flush line 236 so that the sheath 220 can be flushed with saline or radiopaque contrast during the procedure as desired. The flush line 236 can also be used as a second point of aspiration during portions of the procedure as described more fully below. The hemostasis valve 234 can be a static seal-type passive valve, or an adjustable-opening valve such as a Tuohy-Borst valve or rotating hemostasis valve (RHV). The hemostasis valve 234 can be integral to the access sheath 220, or the access sheath 220 can terminate on the proximal end in a female Luer adaptor to which a separate hemostasis valve 234 component, such as a passive seal valve, a Tuohy-Borst valve or rotating hemostasis valve may be attached. In an implementation, the valve 234 has an adjustable opening that is open large enough to allow removal of devices that have adherent clot on the tip without causing the clot to dislodge at the valve 234 during removal. Alternately, the valve 234 is removable and is removed when the catheter tip is being removed from the sheath 220 to prevent clot dislodgement at the valve 234.


Referring again to FIG. 1, the arterial sheath system 200 can include one or more sheath dilators 250 and a sheath guidewire 270. The sheath guidewire 270 can be inserted first into the artery using standard vascular access techniques such as a micropuncture technique or Modified Seldinger technique. The sheath dilator 250 allows for smooth insertion of the access sheath 220 through a puncture site in the arterial wall. The dilator 250 can be inserted into the access sheath 220 and then the two components can be inserted together over the sheath guidewire 270 into the artery. The distal end 256 of the dilator 250 can be generally tapered to allow the dilator 250 to dilate the needle puncture site as it is being inserted through the arterial wall into the artery. The tapered distal end 256 can be generally between 6 and 12 degrees total included angle (relative to a longitudinal axis of the dilator), with a radiused leading edge.


An inner lumen of the dilator 250 can accommodate the sheath guidewire 270, and can have an inner diameter of between 0.037″ to 0.041″ to correspond to a sheath guidewire 270 of between 0.035″ to 0.038″. Alternately, the inner lumen of the dilator 250 can be between 0.020″ to 0.022″ to accommodate a sheath guidewire 270 of between 0.014″ to 0.018″. Alternately, the dilator 250 can be a two part dilator with an inner dilator and an outer dilator. The outer dilator can have an inner diameter of between 0.037″ to 0.041″, and the inner dilator can have an inner diameter of between 0.020″ to 0.022″. In use, the sheath 220 can be inserted into the artery with the outer dilator with a sheath guidewire 270 between 0.035″ and 0.038″. The sheath guidewire 270 may then be removed and replaced with the inner dilator and a smaller guidewire of between 0.014″ and 0.018″, and the access sheath 220 can then be advanced further distally to the desired site in the carotid artery.


To insert the arterial sheath 220 initially over the sheath guidewire 270 into the artery, the dilator taper 256 can have a certain stiffness and taper angle to provide the adequate dilating force on the arterial puncture site. However, to safely reach the petrous portion of the ICA, it may be desirable to have a sheath dilator 250 with a softer and/or longer taper at a distal end than that used for initial arterial access. In an implementation, the access sheath system 200 can include two or more tapered dilators. The first tapered dilator can be used with the arterial access device to gain entry into the artery, and is thus sized and constructed in a manner similar to standard introducer sheath dilators. Example materials that may be used for the tapered dilator include, for example, high density polyethylene, 72D PEBAX, 90D PEBAX, or equivalent stiffness and lubricity material. A second tapered dilator may be supplied with a softer distal section or a distal section that has a lower bending stiffness relative to the distal section of the first tapered dilator, and/or a longer taper length. That is, the second dilator has a distal region that is softer, more flexible, or articulates or bends more easily than a corresponding distal region of the first dilator. The distal region of the second dilator thus bends more easily than the corresponding distal region of the first dilator. In an implementation, the distal section of the first dilator has a bending stiffness in the range of 50 to 100 N-mm2 and the distal section of the second dilator has a bending stiffness in the range of 5 to 15 N-mm2. The second dilator (which has a distal section with a lower bending stiffness) may be exchanged with the initial, first dilator such that the access sheath 220 may be advanced into the internal carotid artery and around curvature in the artery without undue force or trauma on the vessel due to the softer distal section of the second dilator.


The distal section of the soft, second dilator may be, for example, 35 or 40D PEBAX, with a proximal portion made of, for example 72D PEBAX. An intermediate mid portion or portions may be included on the second dilator to provide a smooth transition between the soft distal section and the stiffer proximal section. In an implementation, both dilators have an inner diameter of between 0.037″ to 0.041″. In an alternate implementation, the first dilator has an inner diameter of between 0.037″ to 0.041″ and the second dilator has an inner diameter of between 0.020″ to 0.022″. In yet another implementation, the second dilator is a two part dilator with an inner dilator and an outer dilator, as described above. In an implementation, one or both dilators may have radiopaque tip markers 224 so that the dilator tip position is visible on fluoroscopy. In one variation, the radiopaque marker 224 is a section of tungsten loaded PEBAX or polyurethane that is heat welded to the distal tip of the dilator. Other radiopaque materials may similarly be used to create a radiopaque marker 224 at the distal tip.


In an implementation, the access sheath 220 includes a proximal extension 240 that extends between the connector 226 and the proximal hemostasis valve 234. In the transcarotid configuration of the system, it may be desirable to move the proximal hemostasis valve 234 away from the distal tip of the access sheath 220, effectively elongating or lengthening the proximal portion of the access sheath that is outside the body while maintaining the length of the insertable sheath body portion 222. This allows the user to insert devices into the proximal hemostasis valve 234 of the access sheath 220 from a point further away from the target site and therefore away from the x-ray source and/or image intensifier used to image the target site fluoroscopically, thereby minimizing radiation exposure of the user's hands and also his or her entire body. In this implementation, the proximal extension 240 can be in the range between 10 and 25 cm, or between 15 and 20 cm. In either the transcarotid or transfemoral configuration, it may also be desirable to provide a section of the access sheath 220 that is fluidly connected to the access sheath aspiration line, but which may extend proximally from the aspiration line connection. This will allow users to pull devices out of the flow of blood from the sheath tip to the aspiration line, without completely removing the device from the access sheath 220.


In an alternate implementation, it may also be desirable to intermittently isolate this proximal portion 240 from the sheath body 222. In an implementation, as shown in FIG. 4, the connector 226 includes a valve 242 that can close off the fluid connection between the sheath body 222 and the proximal portion 240 of the access sheath 220, including the aspiration line 230, proximal extension 240 and proximal hemostasis valve 234. This can allow the distal portion of a catheter, retrievable stent device, or other thrombectomy device to be pulled into this proximal extension portion 240, the valve 242 closed to fluidly isolate the sheath body 222 from the proximal portion of the sheath, and then the proximal hemostasis valve 234 to be widely opened or removed, or the entire proximal extension portion 240 of the sheath 220 removed, without arterial bleeding from the sheath 220. The proximal extension 240 can be at least as long as the distal luminal portion 222 of the spined catheter 320 so that the distal luminal portion 322 may be pulled entirely into the proximal extension 240 and the valve 242 closed off before the proximal hemostasis valve 234 is widely opened to remove the catheter 320 entirely from the sheath 220.


Alternately, after the thrombectomy device or other interventional device is pulled into this proximal extension portion 240 and the sheath body 222 closed off via the valve 242, a portion of the thrombectomy device, such as the distal luminal portion 322 of the aspiration catheter 320, may remain in the proximal extension 240 and be flushed or otherwise cleared by creating flow from the flush line to the aspiration lines to dislodge clot without fully removing the device 320 from the access sheath 220. This ability to flush and clear the thrombectomy device without fully removing the thrombectomy device may reduce bleeding, time, and risk of air emboli during the steps between thrombectomy attempts. Also, withdrawing the thrombectomy device into the proximal extension 240 without fully removing it from the sheath body 222 while flushing and clearing also minimizes operator and staff exposure to blood and debris associated with device cleansing. In any of these implementations, the proximal extension tubing is clear so that the flush solution and presence/absence of embolic debris or air is clearly visible through the tubing.


The proximal extension portion 240 of the access sheath 220 can be provided as a separate, removable component that can be attached to any sheath with a standard connection on the proximal end. As shown in FIG. 5, a proximal component 280 includes a connector 285 that can attach to a proximal hub 15 of a standard sheath 10. The coupled components can create an assembly with the configuration and features of access sheath 220. In this implementation, the user can select from any of several already available sheaths of appropriate length, shape, and mechanical characteristics for the procedure, and perform the steps of the procedure described in this disclosure. The removable proximal component 280 can include the Y-arm connector 226, aspiration line 230, proximal extension 240, proximal hemostasis valve 234 and flush line 236, along with the valve connectors 232 and 238 terminating the aspiration line 230 and flush line 236 respectively. A connector 285 can couple to the proximal connector 226 on the sheath 220. In an implementation as shown in FIG. 6, the connector 285 is configured to minimize the flow resistance through the sheath 10 and into the proximal portion 280. For example, instead of a standard male-female Luer connection, the connector 285 can include an adaptor 60 with an inner lumen and surface that matches a standard female Luer connector 62 typically found on sheaths, a seal element 64 that seals between the adaptor 60 and the sheath female Luer 62, and a rotating nut 66 that engages the thread elements of the female Luer 62 and couples the adaptor 60 and Luer 62 together such that the seal 64 is compressed and can seal against fluid and air vacuum and pressure. Again with respect to FIG.5, the proximal component 280 may also include a valve 242 on the Y-arm connector 226, so that when the proximal component 280 is attached to a sheath 10, the proximal section may be selectively open or closed to fluid connection with the sheath 10. A similar type of connection can be made for connector 232 connecting the sheath aspiration line 230 to an aspiration source.


In a preferred implementation, the proximal connection has a proximal extension length of about 22 cm, a Y-arm connector of about 7 cm, and a proximal hemostasis valve of length about 5 cm for a total length of about 34 cm.


It may be desirable to transiently occlude the carotid artery during the intervention to arrest antegrade flow of emboli during portions of the procedure. In an implementation, as shown in FIG. 7, the access sheath 220 includes an occlusion balloon 246 on the distal tip of the sheath body 222. An additional lumen in sheath body 222 can be connected to an inflation line 248 and fluidly connects the balloon 246 to the inflation line 248. An inflation device is attached to inflation line 248 to inflate the occlusion balloon 246. In this implementation, the balloon 246 is inflated when carotid artery occlusion is desired.


In some instances it is desirable to keep the sheath tip as small as possible during sheath insertion to minimize the diameter of the arterial puncture, but to expand the opening of the sheath 220 after it has been inserted into the vessel. At least one purpose of this feature is to minimize the effect or creation of distal emboli during pull back of an aspiration catheter 320 or other thrombectomy device into the sheath 220. During a thrombectomy procedure, the thrombus may be “pulled back” into a distal opening 221 of the sheath 220 on a device that has captured the thrombus. If the distal tip of the sheath 220 is enlarged relative to its initial size, or flared into a funnel shape, the chance of pieces of the thrombus breaking off and causing emboli is minimized because the larger size or funnel shape of the sheath tip is more likely to accommodate the emboli being drawn into it without being split into multiple pieces. This creates a better clinical outcome for the patient. In an implementation of the access sheath, the distal portion of the sheath body 222 is a material and/or construction such that the tip can be expanded after the sheath 220 is inserted into the artery and positioned in its desired location. In an implementation, the distal region of the sheath has an ID of about 0.087″ can be enlarged to a diameter of about 0.100″ to 0.120″ although the size may vary and/or be flared.


Examples of expanding distal tip constructions include covered braided tips that can be shortened to expand. Another example of an expanding distal tip construction is an umbrella or similar construction that can open up with mechanical actuation or elastic spring force when unconstrained. Other mechanisms of expandable diameter tubes are well known in the art. One particular implementation is a sheath made of material that is deformable when expanded using a high pressure balloon. Co-pending U.S. Patent Publication number 2015/0173782, filed on Dec. 19, 2014, describes exemplary devices and is incorporated herein by reference in its entirety. Construction of such features are described in co-pending Publication number 2015/0173782.


The distal end region of the sheath body 222 also may vary in the location, size and number of openings. The sheath body 222 may incorporate one or more openings near the distal end region of the sheath 220 that allow for fluid flow between the lumen 223 of the sheath body 222 and the vasculature within which the sheath 220 is positioned. The one or more openings can be sized to allow at least the luminal portion 322 of the aspiration catheter 320 to extend therethrough. The one or more openings may be sized larger than the outer diameter of the luminal portion 322 such that the one or more openings form an elongate mouth, slot or notch in a distal end region of the sheath body 222. The one or more openings may be formed within a region of the side wall of the sheath body 222 just proximal to the distal end, such that the opening is located at least 0.25 mm, 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 2.5 mm, 3.0 mm, 3.5 mm, or 4.0 mm or greater from the distal end of the sheath body 222. The one or more openings may be a plurality of openings forming a porous region near the distal end region of the sheath body 222 wherein at least one of the pluralities of openings is sized large enough to allow one or more components of the system to exit the lumen 223 of the sheath body 222. In some implementations, the one or more openings includes a distal opening 221 from the lumen 223 of the sheath body 222 (see FIGS. 4 and 12C). In some implementations, the one or more openings includes an elongate, distal mouth forming a side opening 1219 on a first side of the sheath body 222 located near a distal end region (see FIG. 12C). The side opening 1219 may be located at least 0.25 mm or more from the distal end of the sheath body 222. The side opening 1219 may having a diameter that is at least as large as the outer diameter of the distal luminal portion 322 of the spined catheter 320. Preferably, the side opening 1219 has a diameter that is at least 1.5×, 2×, 2.5×, or 3× as large as the outer diameter of the distal luminal portion 322. In another implementation, the sheath body 222 includes a pair of side openings 1219 on opposing and/or adjacent sides of the sheath body 222 near the distal end region. In another implementation, the sheath body 222 includes a distal opening 221 from the lumen 223 and one or more elongate side openings 1219 from the lumen 223. It should be appreciated that the sheath body 222 can be rotated around the longitudinal axis A such that the one or more side openings 1219 are positioned to allow for distal extension of the catheter 320 from the side openings 1219 in a desired direction relative to the longitudinal axis A of the sheath 220. Inclusion of a wide-mouthed side opening 1219 can allow for a range of exit angles for the catheter 320 from a position substantially (i.e. very nearly) parallel to the sheath body 222 to a position that is at an angle to the sheath body 222, for example substantially perpendicular or at a right angle to the sheath body 222, as well as greater than 90° angle. This arrangement can be critically important in situations where there is severe angulation within the vessel being traversed or where a bifurcation is present. Often, tortuous segments in vessels and bifurcations have severe angulations to 90° or greater angle up to 180°. Classic severe angulation points in the vasculature can include the aorto-iliac junction, the left subclavian artery takeoff from the aorta, the brachiocephalic (innominate) artery takeoff from the ascending aorta as well as many other peripheral locations.


Referring again to FIG. 1, as mentioned above the catheter system 300 can include a spined aspiration catheter 320 having a flexible, distal luminal portion 322 and a rigid, proximal spine 330. The outer diameter of the distal luminal portion 322 as well as the flexibility and lubricity of the luminal portion 322 paired with the rigid spine 330 allow for the spined aspiration catheter 320 to navigate to the site of occlusions in the cerebral vasculature compared to other systems configured to navigate the cardiac vasculature. The systems described herein can reach occlusions in a region of the anatomy that has a long, tortuous access route. The route may contain stenosis plaque material in the aortic arch and carotid and brachiocephalic vessel origins, presenting a risk of embolic complications. Further, cerebral vessels are usually more delicate and prone to perforation than coronary or other peripheral vasculature. The catheter systems described herein can provide for neurovascular interventional procedures more easily due to its ability to overcome these access challenges. The catheter systems described herein are designed for navigating tortuosity rather than pushing through it. U.S. Patent Publication Number 2015/0174368, filed on Dec. 12, 2014, and U.S. Patent Publication Number 2015/0173782, filed on Dec. 19, 2014, which are incorporated herein by reference, describe features of catheter devices that can navigate the tortuous anatomy of the cerebral arteries.


The length of the distal luminal portion 322 can vary. In some implementations, the length of the distal luminal portion 322 extends from a region near the distal tip of the access sheath body 222 to the site of the occlusion in the carotid artery, forming a proximal overlap region 120 with the distal end of the access sheath 220 (see FIG. 2B). Taking into account the variation in occlusion sites and sites where the access sheath distal tip may be positioned, the length of the distal luminal portion 322 may range from about 10 cm to about 25 cm. The length of the distal luminal portion 322 is less than the length of the sheath body 222 of the access sheath 220, such that as the spined aspiration catheter 320 is retracted into the sheath body 222 there remains a seal between the overlap region 328 of the spined aspiration catheter 320, and the inner diameter of the sheath body 222.


The catheter systems described herein can incorporate multiple spined catheters that are nested inside one another to allow for an extended reach into the tortuous anatomy. For example, a first spined catheter 320 having an outer diameter sized to be received within the lumen of the sheath body 222 may have a second spined catheter 320 extending through the inner lumen of the first spined catheter 320. The second spined catheter 320 can be extended using its proximal spine beyond a distal end of the first spined catheter 320 such that the smaller diameter second spined catheter 320 can reach a more distal region of the vasculature, particularly one having a narrower dimension. In this implementation, the first spined catheter 320 can act as a support catheter for the second spined catheter 320. The second spined catheter 320 can have an inner lumen that fluidly communicates with the inner lumen of the first spined catheter 320 that fluidly communicates with an inner lumen of the sheath body 222 forming a contiguous aspiration lumen.


In an implementation, the distal luminal portion 322 of the catheter 320 is constructed to be flexible and lubricious, so as to be able to be safely navigated to the target site, and kink resistant and collapse resistant when subjected to high aspiration forces, so as to be able to effectively aspirate the clot, with sections of increasing flexibility towards the distal end. In an implementation, the distal luminal portion 322 includes three or more layers, including an inner lubricious liner, a reinforcement layer, and an outer jacket layer. The outer jacket layer may be composed of discreet sections of polymer with different durometers, composition, and/or thickness to vary the flexibility along the length of the distal luminal portion 322. In an implementation the lubricious inner liner is a PTFE liner, with one or more thicknesses along variable sections of flexibility. In an implementation, the reinforcement layer is a generally tubular structure formed of, for example, a wound ribbon or wire coil or braid. The material for the reinforcement structure may be stainless steel, for example 304 stainless steel, nitinol, cobalt chromium alloy, or other metal alloy that provides the desired combination of strengths, flexibility, and resistance to crush. In an implementation, the reinforcement structure includes multiple materials and/or designs, again to vary the flexibility along the length of the distal luminal portion 322. In an implementation, the outer surface of the catheter 320 is coated with a lubricious coating such as a hydrophilic coating. In some implementations the coating may be on an inner surface and/or an outer surface to reduce friction during tracking. The coating may include a variety of materials as is known in the art. The spine portion 330 may also be coated to improve tracking through the access sheath 220. Suitable lubricious polymers are well known in the art and may include silicone and the like, hydrophilic polymers such as high-density polyethylene (HDPE), polytetrafluoroethylene (PTFE), polyarylene oxides, polyvinylpyrolidones, polyvinylalcohols, hydroxy alkyl cellulosics, algins, saccharides, caprolactones, and the like, and mixtures and combinations thereof. Hydrophilic polymers may be blended among themselves or with formulated amounts of water insoluble compounds (including some polymers) to yield coatings with suitable lubricity, bonding, and solubility.


The outer diameter of the distal luminal portion 322 can be sized for navigation into cerebral arteries. It is desirable to have a catheter having an inner diameter that is as large as possible that can be navigated safely to the site of the occlusion, in order to optimize the aspiration force. A suitable size for the inner diameter may range between 0.040″ and 0.075″ or may range between 0.040″ and 0.088″, depending on the patient anatomy and the clot size and composition. The outer diameter should be as small as possible while still maintaining the mechanical integrity of the catheter 320. However, at the overlap region 120, the outer diameter (OD) of the catheter 320 approaches the inner diameter (ID) of the access sheath 220, so as to create a sealed area at the overlap region 120 whilst still enabling the catheter 320 to be inserted easily through the sheath 220 and positioned at the desired site. In an implementation, the catheter 320 and access sheath 220 are sized to match at the overlap region 120 with no change in catheter 320 outer diameter (see FIG. 2B). In an implementation, the difference between the catheter OD and the access sheath ID at the overlap region is 0.002″ or less. In another implementation, the difference is 0.003″ or less. In an implementation, the catheter 320 is tapered towards the distal tip of the distal luminal portion 322 such that the distal-most end of the catheter has a smaller outer diameter compared to a more proximal region of the catheter near where it seals with the access sheath. In another implementation, the catheter OD steps up at an overlap portion 328 to more closely match the sheath inner diameter (see FIG. 1). This implementation is especially useful in a system with more than one catheter suitable for use with a single access sheath size. It should be appreciated where the catheter OD of the spined catheter 320 matches the sheath inner diameter or the difference is 0.002″ or less, a seal to fluid being injected or aspirated can be achieved by the overlap portion 328 such that no increase in catheter OD is necessary. A seal to fluid being injected or aspirated between the catheter and the sheath can be achieved by the overlap between their substantially similar dimensions without incorporating any separate sealing structure or seal feature.


In another implementation as shown in FIGS. 8A and 8B, there is a sealing element 336 positioned on the external surface of the proximal end of the distal luminal portion 322. The sealing element 336 can be one or more external ridge features, and can be compressed when the catheter 320 is inserted into the lumen of the access sheath 220. The ridge geometry can be such that the sealing element 336 behaves as an O-ring, quad ring, or other piston seal design. FIG. 8B shows a similar configuration, with the sealing element 336 having a wiper seal configuration such as an inclined surface that is biased against an inner surface of access sheath body 222. Alternately, the seal element 336 may be an inflatable or expandable member such as a balloon or covered braid structure that can be inflated or expanded and provide sealing between the two devices at any time, including after the catheter 320 is positioned at the desired site. An advantage to this implementation is that there is no sealing force being exerted on the catheter 320 during catheter positioning, but rather is applied or actuated to seal after the catheter 320 is positioned.


It should be appreciated that the shape of the proximal end region of the distal luminal portion 322 may have an angled cut compared to the straight cut shown in the FIGS. 8A-8B. It should also be appreciated that the spine 330 may be coupled to a proximal end region of the catheter 320 and/or may extend along at least a portion of the distal luminal portion 322 such that the spine 330 couples to the distal luminal portion 322 a distance away from the proximal end. The spine 330 can be coupled to the portion 322 by a variety of mechanisms including bonding, welding, gluing, sandwiching, stringing, tethering, or tying one or more components making up the spine 330 and/or portion 322. In some implementations, the spine 330 and luminal portion 322 are coupled together by sandwiching the spine 330 between layers of the distal luminal portion 322. For example, the spine 330 can be a hypotube or rod having a distal end that is skived, ground or cut such that the distal end can be laminated or otherwise attached to the layers of the catheter portion 322 near a proximal end region. The region of overlap between the distal end of the spine 330 and the portion 322 can be at least about 1 cm. This type of coupling allows for a smooth and even transition from the spine 330 to the luminal portion 322.


In an implementation, the overlap region is configured to enable sealing against a vacuum of up to 25 inHg, or up to 28 inHg. In an implementation, the overlap region 120 is configured to enable sealing against a pressure of up to 300 mmHg or up to 600 mmHg or up to 700 mmHg with minimal to no leakage. In addition, there may be features that prevent excessive advancement of the spined aspiration catheter 320 beyond the distal end of the access sheath 220. In any implementation that involves a stepped up diameter or protruding feature at the overlap region 328 of the spined aspiration catheter 320, the access sheath body 222 may include an undercut at the tip that prevents the proximal overlap portion of the spined aspiration catheter 320 to exit the sheath body 222.


The distal luminal portion 322 of the catheter 320 can have a radiopaque marker 324 at the distal tip to aid in navigation and proper positioning of the tip under fluoroscopy (see FIG. 1). Additionally, the proximal overlap region 328 of the catheter 320 may have one or more proximal radiopaque markers 1324 (see FIG. 12C) so that the overlap region 120 can be visualized as the relationship between the access sheath distal marker 224 and the catheter proximal marker 1324. In an implementation, the two markers (marker 324 at distal tip and a more proximal marker 1324) are distinct so as to minimize confusion of the fluoroscopic image, for example the catheter proximal marker 1324 may be a single band and the sheath tip marker 224 may be a double band.


The spine 330 of the spined aspiration catheter 320 is coupled to a proximal end region of the distal luminal portion 322. The spine 330 is configured to allow distal advancement and proximal retraction of the catheter 320 through the lumen 223 of the access sheath 220. In an implementation, the length of the spine 330 is longer than the entire length of the access sheath 220 (from distal tip to proximal valve), such as by about 5 cm to 15 cm. As shown in FIG. 1, the spine 330 can include a mark 332 to indicate the overlap between the distal luminal portion 322 of the catheter 320 and the sheath body 222. The mark 332 can be positioned so that when the mark 332 is aligned with the sheath proximal valve 234 during insertion of the catheter 320 through the sheath 220, the spined aspiration catheter 320 is positioned at the distal-most position with the minimal overlap length needed to create the seal between the spined aspiration catheter 320 and the access sheath 220. The spine 330 can include a gripping feature such as a tab 334 on the proximal end to make the spine easy to grasp and advance or retract. The tab 334 can coupled with one or more other components of the system 300, such as a dilator configured to extend through the lumen 323 of the distal luminal portion 322 as will be described in more detail below. The proximal tab 334 can be designed to be easily identifiable amongst the other devices existing in the sheath proximal valve 234, such as guidewires 270 or retrievable stent device wires 500. In an implementation, the spine 330 is colored a bright color, or marked with a bright color, to make it easily distinguishable from guidewire, retrievable stent tethers, or the like.


The spine 330 can be configured with sufficient stiffness to allow advancement and retraction of the distal luminal portion 322 of the spined aspiration catheter 320, yet also be flexible enough to navigate through the cerebral anatomy as needed. Further, the outer diameter of the spine 330 is sized to avoid taking up too much luminal area in the lumen 223 of the access sheath 220 and sheath body 222. In an implementation, the spine 330 is a round wire, with dimensions from 0.014″ to 0.018″. In another implementation, the spine 330 is a ribbon with dimensions ranging from 0.010″ to 0.015″ thick, and 0.015″ thick to 0.025″ thick. The ribbon can have a variety of cross-sectional shapes such as a flat ribbon or curved ribbon forming a c-shape or other shape along an arc. In another implementation, the spine 330 is a hypotube. In an implementation, the spine 330 material is a metal such as a stainless steel or nitinol as well as a plastic such as any of a variety of polymers.


One or more components of the systems described herein may be made from a metal, metal alloy, polymer, a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable materials. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UM: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.


The junction between the distal luminal portion 322 of the catheter 320 and the proximal spine 330 can be configured to allow a smooth transition of flexibility between the two portions so as not to create a kink or weak point, and also allow smooth passage of devices such as guidewires and microcatheters through the continuous inner lumen created by the lumen 223 of the access sheath 220 and the lumen 323 of the luminal portion 322 of the catheter 320. In an implementation, the distal luminal portion 322 has a transition section 326 (see FIG. 1) near where the portion 322 couples to the spine 330 that has an angled cut such that there is no abrupt step transition from the sheath 220 inner lumen 223 to the catheter 320 inner lumen 323. The angled cut can be generally planer. In an alternate implementation, the angled cut is curved or stepped to provide a more gradual transition zone. The distal luminal portion 322 and the spine 330 may be joined by a weld bond, a mechanical bond, an adhesive bond, or some combination thereof. The distal end of the spine 330 may have features that facilitate a mechanical joint during a weld, such as a textured surface, protruding features, or cut-out features. During a heat weld process, the features would facilitate a mechanical bond between the polymer distal luminal portion 322 and the spine 330. In another implementation, such as the catheter system 1300 shown in FIGS. 12A-12B having a spined catheter 1320 and a dilator 1340 extending therethrough, a smooth transition of flexibility between the two portions is formed so as not to kink or create a weak point during advancement of the system 1300. Loss of this smooth flexibility transition can occur upon removal of the dilator 1340 from the spined catheter 1320. The spine 1330 can be intended primarily to withdraw the spined catheter 1320 where risk of kink or weak spot formation is markedly lower.


Because the spined aspiration catheter 320 does not have a lumen that runs its entire length 320 due to the presence of the spine 330 on its proximal end region, traditional flushing and preparation steps, either before use or during the procedure should the lumen of the catheter become clogged, are ineffective. In a traditional single lumen catheter, a syringe is attached to the proximal adaptor of the catheter and the inner lumen may be forcefully flushed with solution. The spined catheter 320 can be supplied with an accessory catheter flushing and clearing device 350 (see FIG. 1). This device 350 may be a tube with a rounded or tapered tip on a distal end and a female Luer connection on the proximal end. The Luer connector allows a syringe to be connected to the device 350. The blunt or tapered tip enables the device 350 to be inserted into either the distal or proximal end of the luminal portion 322 of the catheter 320, without risk of damaging the catheter 320, and the syringe actuated to flush the device. The OD of the clearing device 350 is closely matched with the ID of the luminal portion 322 of the spined catheter 320, such that the spined aspiration catheter 320 may be flushed with enough force to clear out the catheter of debris and aspirated occlusive material. The device 350 may also be used to mechanically clear out any entrapped thrombus in a plunger-type action, the working length of the device 350 can be at least as long as the distal luminal portion 322 of the catheter 320, so that it may be inserted through the entire lumen 323 of the distal luminal portion 322. Flushing may occur in conjunction with plunging the device 350, to more effectively clear the catheter 320 of entrapped thrombus or other embolic material.


In an alternate implementation, the aspiration catheter 320 is a single lumen catheter, for example, the type of catheter described in co-pending application U.S. Patent Publication Number 2015/0174368, filed Dec. 12, 2014. In such an implementation, the catheter may be supplied with or coupled with a tapered co-axial dilator 340 that is generally tubular and has a tapered distal portion that provides a smooth transition between the catheter and a guidewire positioned within the catheter.


The spined aspiration catheter 320 can be navigated through the vasculature over an appropriately-sized microcatheter and guidewire. Alternately, the spined catheter 320 can be supplied with a co-axial dilator 340 (see FIG. 1). The dilator 340 is sized and shaped to be inserted through the internal lumen 323 of the distal luminal portion 322 of the catheter 320 in a coaxial fashion, such that a proximal end region of the dilator 340 aligns side-by-side with the spine 330 of the catheter 320 when in use. The dilator 340 can have a tapered distal tip 346. The length of the dilator 340 can be at least as long as the spined aspiration catheter 320 allowing for the distal tapered tip 346 as a minimum to protrude from the distal end of the luminal portion 322 of the spined catheter 320. The dilator 340 can have an outer diameter that forms a smooth transition to the distal tip of the catheter, and the distal tapered tip 346 that provides a smooth transition down to the guidewire that extends out the inner lumen of the dilator 340. The dilator 340 can be generally tubular along at least a portion of its length. In an implementation, the tapered dilator 340 is designed to accommodate a guidewire that may be in the range of 0.014″ and 0.018″ diameter for example. In this implementation, the inner luminal diameter may be between 0.020″ and 0.024″. The tapered distal tip 346 may be in range from 1.5 cm to 3 cm.


It should be appreciated that the dilators described herein for use with the spined catheters can vary in their configuration. For example, as described above the dilator 340 can be a co-axial dilator 340 that is generally tubular and has a tapered distal portion that provides a smooth transition between the catheter 320 and a guidewire positioned within the catheter 320. The tubular body of the dilator 340 can extend along the entire length of the catheter 320. Alternatively, the dilator 340 can incorporate a proximal spine that aligns side-by-side with the spine of the catheter 320. The proximal spine can be positioned co-axial or eccentric to a distal end region of the dilator 340. The co-axial proximal spine of the dilator 340 can have a lumen extending through it. Alternatively, the dilator 340 can be a solid rod having no lumen. The solid rod dilator can be formed of a malleable material that skives down to have a narrow outer diameter (e.g. 0.010″-0.014″) such that the dilator can be shaped to whatever angle or shape is desired by the user, similar to how a guidewire may be used. In this configuration, the catheter system does not include a guidewire or microcatheter. Such a dilator has a benefit over a microcatheter in that it can have an outer diameter that is 0.003″-0.010″ smaller than the inner diameter of the spined catheter 320.


The dilator 340 may have a proximal female Luer adaptor 348 at a proximal end to allow the dilator 340 to be flushed with a syringe. The dilator 340 may also incorporate a clip feature at a proximal end allowing the dilator 340 to be the material of the dilator 340 can be flexible enough and the taper distal tip 346 can be long enough to create a smooth transition between the flexibility of the guidewire and the flexibility of the catheter. This configuration can facilitate advancement of the catheter 320 through the curved anatomy and into the target cerebral vasculature. In an implementation, the distal end of the dilator 340 has a radiopaque marker 344 and/or a marker 343 at the proximal end of the taper distal tip 346. The marker material may be a platinum/iridium band, a tungsten, platinum, or tantalum-impregnated polymer, or other radiopaque marker.


The dilator 340 can be constructed to have variable stiffness between the distal and proximal ends of the dilator 340. For example, the distal most section that extends beyond the distal end of the luminal portion 322 of the catheter 320 can be made from a more flexible material, with increasingly stiffer materials towards the more proximal sections. In some implementations, the dilator 340 can be a spined dilator having a proximal spine as will be described in more detail below. The proximal end of the dilator 340 can include a tab 1364 that allows the dilator 340 to lock with the tab 334 on the proximal end of the spine 330 of the catheter 320, such that the two components (the spined catheter 320 and the dilator 340) may be advanced as a single unit over the guidewire (see FIG. 12A). In some implementations, the tab 334 of the catheter 320 can form a ring having a central opening extending therethrough. The tab 1364 of the dilator 340 can have an annular detent with a central post. The central post of the tab 1364 can be sized to insert through the central opening of the tab 334 such that the ring of the tab 334 is received within the annular detent of tab 1364 forming a singular grasping element for a user to advance and/or withdraw the catheter system through the access sheath. The tab 1364 may be affixed to the dilator 340, or may be slidable on the dilator 340 to accommodate different relative positions between the dilator 340 and the spined catheter 320.



FIGS. 12A-16 provide additional views of a spined aspiration catheter and dilator system 1300 as described elsewhere herein. FIGS. 12A-12B show the spined aspiration catheter 1320 having a dilator 1340 extending through an aspiration lumen 1323 of the distal luminal portion 1322. As described elsewhere herein, the catheter 1320 can have a proximal spine 1330 having a tab 1334 and a distal luminal portion 1322 having an aspiration lumen 1323. The spine 1330 can extend between the distal luminal portion 1322 and the tab 1334. The dilator 1340 can be received within the aspiration lumen 1323 of the spined catheter 1320. The dilator 1340 can include a distal dilator portion 1360 and a proximal spine 1362. The dilator portion 1360 can extend between a distal tip 1346 of the dilator 1340 to the start of the proximal spine 1362. When engaged with the catheter 1320, the dilator portion 1360 of the dilator 1340 may extend through an entire length of the distal luminal portion 1322 of the catheter 1320 such that the dilator tip 1346 extends a fixed distance beyond a distal end of the distal luminal portion 1322 of the catheter 1320 providing a smooth transition for improved tracking. The dilator tip 1346 can be tapered as described elsewhere herein and can be soft, atraumatic and flexible to the vessel wall to facilitate endovascular navigation to an embolus in a tortuous anatomy compared to dilators typically used for percutaneous arterial access, which are meant to bluntly dissect through tissue and artery wall.


The dilator 1340 is shown in a locked configuration with the catheter 1320 configured for improved tracking through a tortuous and often diseased vasculature in acute ischemic stroke. The dilator portion 1360 can include one or more detents on an outer surface of the dilator portion 1360. The detents can be located near a proximal end region and/or a distal end region of the dilator portion 1360. The detents are configured to lock with correspondingly-shaped surface features on the inner surface of the lumen 1323 through which the dilator portion 1360 extends. The dilator 1340 can include a dilator tab 1364 on a proximal end of the proximal spine 1362 of the dilator 1340, which as discussed above can be configured to connect and lock with a corresponding feature on the proximal end region of the catheter spine 1330, for example via one or more detents or other surface features. Thus, the dilator 1340 and the catheter 1320 can have more than a single point of locking connection between them. The proximal spine 1362 of the dilator 1340 can extend between the dilator portion 1360 and the tab 1364 of the dilator 1340. The dilator portion 1360 can be a tubular element as described elsewhere herein that forms a guidewire lumen running a length of the dilator portion 1360 (and an entire length of the distal luminal portion 1322 of the spined catheter 1320). It should be appreciated that the entire dilator 1340 can be tubular element configured to receive a guidewire through the spine 1362 as well as the dilator portion 1360. The proximal end of the dilator portion 1360, i.e., the transition section 1326 between the dilator portion 1360 and the proximal spine 1362, may include a “step up” to smooth the transition between the distal luminal portion 1322 of the catheter 1320 and the dilator portion 1360 of the dilator 1340. The transition section 1326 can incorporate an angled cut such that there is no abrupt step transition from the sheath 1220 inner lumen 1223 to the catheter 1320 inner lumen 1323. Accordingly, the spined aspiration catheter-dilator 1300 may be smooth to the vascular wall it interfaces with.


The proximal spine 1362 of the dilator 1340 may have a similar stiffness and character as the spine 1330 of catheter 1320. More particularly, one or both of the spines 1362, 1330 may be stiff and/or kink resistant. Furthermore, one or both of the spines 1362, 1330 may have a stiffness to allow pushing the distal portions, i.e., the combined distal luminal portion 1322 and dilator portion 1360, through an access sheath or a guide-sheath while producing a very low profile. In an embodiment, one or both of the spines 1362, 1330 includes a stiff wire.


The catheter tab 1334 and the dilator tab 1364 can be removably connected with one another. More particularly, the tabs 1334, 1364 may have a locked configuration and an unlocked configuration. In the locked configuration, the dilator tab 1364 can be engaged with the catheter tab 1334. In the unlocked configuration, the dilator tab 1364 may be disengaged from the catheter tab 1334. The dilator tab 1364 may attach, e.g., click or lock into, the catheter tab 1334 in a fashion as to maintain the relationships of corresponding section of the spined dilator 1340 and the spined catheter 1320 in the locked configuration. Such locking may be achieved by, e.g., using a detent on the dilator tab 1364 that snaps into place within a recess formed in the catheter tab 1334, or vice versa. In some implementations, the spine 1330 of the spined catheter 1320 can run alongside or within a specialized channel of the dilator spine 1362. The channel can be located along a length of the dilator spine 1362 and have a cross-sectional shape that matches a cross-sectional shape of the catheter spine 1330 such that the spine 1330 of the catheter 1320 can be received within the channel and slide smoothly along the channel bi-directionally. Once the spined catheter 1320 and spined dilator 1340 are fixed, the combined system, i.e., the spined aspiration catheter-dilator 1300 may be delivered to a target site, for example through the lumen 223 of the access sheath 220 described elsewhere herein.


Referring to FIG. 12B, a spined aspiration catheter-dilator 1300 having a spined catheter 1320 and a spined dilator 1340 in an unlocked configuration is illustrated in accordance with an embodiment. When the spined aspiration catheter-dilator 1300 is positioned at the target site, as discussed herein, the dilator tab 1364 can be unlocked from the catheter tab 1334. The spined dilator 1340 may be withdrawn and the spined catheter 1320 may be used, e.g., for aspiration or for wire or balloon delivery.


Referring to FIG. 13, a cross-sectional view, taken about line A-A of FIG. 12B, of a spined catheter 1320 coaxially aligned with a spined dilator 1340 is illustrated in accordance with an embodiment. The cross-section illustrates a portion of the catheter-dilator having the dilator portion 1360 received within the aspiration lumen 1323 of distal luminal portion 1322. The lumen 1323 may have an inner diameter in a range up to 0.072 inches, although a larger or smaller inner diameter is possible (larger or smaller possible). The wall of the distal luminal portion 1322 may resist kinking or ovalizing to provide maximum diameter for aspiration. The dilator portion 1360 may be received in the distal luminal portion 1322 in a slip fit. Thus, in an embodiment, an outer dimension of the dilator portion 1360 may be less than the inner diameter of the distal luminal portion 1322. For example, the lumen 1323 may have a diameter of 0.072 inches and the dilator portion 1360 may have an outer dimension of 0.070 inches.


Referring to FIG. 14, a cross-sectional view, taken about line B-B of FIG. 12B, of a spined catheter 1320 after removal of a spined dilator 1340 is illustrated in accordance with an embodiment. The cross-section illustrates the distal luminal portion 1322 after the dilator portion 1360 has been retracted and/or removed. The distal luminal portion 1322 has an inner wall 1321 defining the lumen 1323. The lumen 1323 may be circular, as shown, or may have any other shape. In an embodiment, the effective diameter of the lumen 1323 ranges up to 0.072 inches.


Referring to FIG. 15A, a spined aspiration catheter-dilator system 1300 having a spined catheter 1320 and a spined dilator 1340 in a locked configuration is illustrated in accordance with an embodiment. In an embodiment, the spine 1330 and dilator 1340 may have an outer dimension that is substantially similar over an entire length. For example, rather than converging to a smaller dimension between the dilator portion 1360 and the dilator spine 1362, the dilator spine 1362 may have a same dimension as the dilator portion 1360. Thus, a catheter-dilator having a substantially same cross-sectional area over at least a majority of its length may be provided. As discussed above, the spine dilator 1340 and the spine catheter 1320 may have corresponding tabs 1334, 1364 that engage in a locked configuration and disengage in an unlocked configuration.


Referring to FIG. 15B, a spined aspiration catheter-dilator having a spined catheter 1320 and a spined dilator 1340 in an unlocked configuration is illustrated in accordance with an embodiment. The spined dilator 1340 may be removed from the spined catheter 1320 in a manner similar to that described above. In an embodiment, the spined aspiration catheter-dilator may have a similar cross-sectional area over a majority of its length, and thus, the shapes of the spined catheter 1320 and the spined dilator 1340 may be complimentary. For example, the spine 1330 may have a cross-sectional area along an arc, such as a quarter circle, and thus, a cross-sectional area of the dilator spine 1362 may be three quarters of a circle. As such, the spine 1330 may conform to the dilator spine 1362 to provide an overall cross-sectional area of a full circle.


Referring to FIG. 16, a schematic view of a spined catheter 1320 having a distal luminal portion 1322 having an inner lumen 1323 located in a neurovascular anatomy is illustrated in accordance with an embodiment. Used in conjunction with an access sheath 1220 having a sheath body 1222 and an inner lumen 1232, in an embodiment where the spined catheter 1320 reaches the ICA and the distance to embolus E is consistently felt to be less than 20 cm, one would see that the distal luminal portion 1322 having a length of 25 cm would allow for an overlap region 1120 with the access sheath 1220 to create a seal. The overlap region 1120 may have a length of a few centimeters, and the may vary depending on the distance from the embolus E to the distal end of the distal luminal portion 1322, e.g., depending on how far the spined catheter 1320 is advanced relative to the access sheath 1220.


As described elsewhere herein, the luminal area available for aspiration of the embolus is greater using the spined catheter 1320 as compared to an aspiration system having a conventional large bore catheter in an access sheath. More particularly, the combined volume of the luminal area of the spined catheter 1320 and the luminal area of the access sheath 1220 proximal to the distal luminal portion 1322 is greater than the luminal area of the large bore catheter along the entire length of the system. Thus, the likelihood of removing the embolus in a single aspiration attempt may be increased. More particularly, the stepped up luminal diameter along the spine 1330 may enable a greater aspiration force to be achieved resulting in improved aspiration of the embolus. The stepped up luminal diameter may also increase the annular area available for forward flushing of contrast, saline, or other solutions while devices such as microcatheters or tapered inner members are coaxially positioned in the spined catheter and access sheath. Thus, the ease and ability to perform angiograms during device navigation may be improved.


The disclosed systems may be supplied with ancillary devices that are particularly configured to be used with the system. It should be appreciated that reference to one implementation of an access sheath system or aspiration catheter system is not intended to be limited and that the ancillary devices described herein can be used with any of the systems having any of a variety or combination of features described herein. For example, where an access sheath is described below it should be appreciated that one or more features of any of the access sheaths or access sheath systems described herein can be incorporated. Similarly, where a spined catheter is described below one or more featured of any of the spined catheters or spined catheter systems described herein can be incorporated.


In an implementation, the system includes a microcatheter 400 (see FIG. 1). The microcatheter 400 can be configured to be particularly suited for navigation in the cerebral vasculature. The microcatheter 400 may be used in place of the tapered dilator 340 to help navigate the spined catheter 320 to the desired site. As such, it may include means at the proximal end to lock the spine 330 to the microcatheter 400, so that so that the two components (the spined catheter 320 and the microcatheter 400) may be advanced as a single unit over the guidewire. In some instances the microcatheter 400 is advanced ahead of the catheter 320, to provide support as the catheter 320 is advanced, or to cross the occlusion and perform an angiogram distal to the occlusion. In this case, the length of the microcatheter 400 can be longer than the spined catheter 320 by about 10 to 20 cm. The microcatheter 400 may also be used to deliver a retrievable stent device 500 to the occlusion. In this case, the microcatheter 400 can have an inner diameter suitable for delivery of the retrievable stent device 500, for example, in the range 0.021″ to 0.027″ and with a PTFE inner liner. The microcatheter 400 can be at least about 5-10 cm longer or at least about 5-20 cm longer than the overall length of the spined catheter 320 to allow the microcatheter 400 to extend beyond the distal end of the aspiration catheter 320 during navigation.


In an implementation, the system includes a retrievable stent device 500 with a distal expandable section 510, which is sized and configured to be delivered through the microcatheter 400, as shown in FIG. 9. The retrievable stent device 500 may be used in conjunction with the other components of the system to aid in removal of the occlusion. The retrievable stent device 500 may also be used to quickly restore flow to the occluded artery during the thrombectomy procedure. Examples of retrievable stent devices include the Solitaire Revascularization Device (Medtronic) or the Trevo Stentriever (Stryker).


In a method of use, the retrievable stent device 500 is used to assist in bringing thrombus into the catheter 320 during an aspiration step, or clearing the catheter 320 that may become clogged during the aspiration step. In an implementation, the retrievable stent device 500 is configured to be particularly suited for performing these functions. For example, as shown in FIG. 10A, the distal end of the expandable portion 510 of the device 500 has multiple struts or elements 520 that come together at the distal tip to close off the distalmost end, such that the device allows blood flow across the device, but captures the thrombus pieces as the device 500 is pulled into the catheter 320, and subsequently through the catheter 320 and out the distal end. Alternately, the distal end 520 is a filter element or a balloon element.


In another example, in FIG. 10B, the retrievable stent device 500 includes two or more segments with one or more proximal segments 510a configured to be expanded in the catheter distal inner lumen while one or more distal segments 510b are expanded across the occlusion as is done with prior retrievable stent devices. Alternately, as seen in FIG. 10C, the retrievable stent device 500 has a very long expandable portion 510, such that a proximal portion of the expandable portion may be expanded in the catheter distal inner lumen while the distal portion is expanded across the occlusion. In all these implementations, the proximal end of expandable section 510 has minimal structural elements that will allow the expandable section to be pulled easily into the lumen of the catheter 320, and out of the access sheath 320, so as minimize impediment of thrombus aspiration through the device. In these examples, the expandable portion 510 is still engaged with the clot even when the clot is aspirated into the catheter 320, and if the catheter 320 becomes corked, the device 500 is well-positioned to clear the clot when it is pulled back. Once the retrievable stent device 500 has been removed from the luminal portion 322 of the catheter 320, additional aspiration can be applied to the site through the catheter 320 if it is still partially or fully occluded. This step would not be possible if the catheter 320 remained clogged; the catheter would have to be removed and cleared outside the patient before being reinserted for additional aspiration. This configuration of retrievable stent device 500 can be used with either a conventional single lumen aspiration catheter, or a spined aspiration catheter 320.


The implementations of device 500 as shown in FIGS. 10A-10C may be used with known thrombectomy devices and methods to address the issue of catheters clogging during thrombus aspiration.


In an implementation, the system includes an aspiration source 600, as shown in FIG. 2A or FIG. 3. The aspiration source 600 can be attached to the aspiration line 230 on the access sheath 220. Examples of aspiration source 600 include a syringe or an active aspiration pump. The aspiration source 600 may be connected to a delivery location, such as a receptacle. The receptacle and source of aspiration 600 may be separate, such as a mechanical or electromechanical fluid pump whose outlet is connected to a blood collection reservoir or may be combined into a single device such as a syringe or syringe pump. Alternately, the blood collection reservoir is connected to a source of vacuum such as a hospital vacuum line or an air vacuum pump, and is thus the receptacle as well as the source of aspiration. A filter and/or a check valve may be coupled with the aspiration source. The pump may be a positive displacement pump such as a diaphragm or piston pump, a peristaltic pump, centrifugal pump, or other fluid pump mechanism known in the art.


In an implementation, the aspiration source is a variable state or multi-state aspiration source, and includes a mechanism to control the level of aspiration, for example by modifying the vacuum level in the vacuum pump, by modifying the power to the motor of a positive displacement, peristaltic or centrifugal pump, or modifying the syringe pull back speed in the syringe or syringe pump. Alternately, the aspiration rate may be varied by providing an element with variable resistance to flow, for example parallel flow paths that can switch between a high and low flow resistance path, flow orifices or lumens that can be variably opened, or other means to vary flow resistance. In an example, the aspiration source is configured to have two levels of aspiration: a high level of aspiration to be used when the catheter is in contact with the thrombotic material, to aspirate the thrombotic occlusion, and a low level of aspiration to be used during steps in the procedure that are high risk of causing distal emboli, for example crossing the lesion or when flow is restored to the vessel when a retrievable stent device is expanded.


In another example, as shown in FIG. 11, the aspiration source 600 further includes a flow sensor 275 that senses flow in the aspiration line 230, coupled to a controller that controls the level of aspiration. The aspiration source 600 can increase in aspiration level when the flow rate is slow and decrease when the flow rate is increased. In this manner, the force is greatest when the catheter is clogged or partially clogged, but decreases to a minimal level when there is free flow to ensure protection from distal emboli but limit the volume of aspirated blood. In this manner, the system optimizes the thrombus aspiration while limiting the amount of blood aspirated. Alternately, the aspiration source 600 can include a vacuum gauge. When the flow in the catheter 320 is blocked or restricted the pump creates a higher level of vacuum. In this example the aspiration force may be configured to rise when higher vacuum is detected.


In yet another aspiration source implementation, the aspiration source 600 provides a cyclic level of aspiration force, for example, an aspiration force that cycles between a high level of vacuum to a lower level of vacuum at a set frequency, or from a high level of vacuum to no vacuum, or from a high level of vacuum to a pressure source. A cyclic aspiration mode may provide a jack-hammer type force on the thrombus and increase the ability to aspirate the thrombus through the catheter. The cyclic aspiration force may be enabled through solenoid valves, a programmable pump motor, or the like. In an implementation, cyclic aspiration is applied only when clogged or restricted flow is detected in the aspiration line, either through low flow or high vacuum, as discussed above, and at other times, the aspiration source reverts to a low level of flow, or be turned off. This configuration may be controlled by the user, or controlled automatically via a feedback loop to the aspiration source.


In an implementation, the system includes a mechanism for passive reverse flow that is configured to be connected to the aspiration line on the access sheath. For example, the aspiration line is connected to a lower pressure site such as a central vein, or an external receptacle set to zero or negative pressure.


In an implementation as shown in FIG. 11, the flush line 236 may be connected via stopcock 238 to a syringe 286 that may hold saline fluid or radiopaque contrast. Additionally the flush line 236 may be connected to a flush source 288, for example, a pressurized bag of saline. A valve 292 can control flow from the flush source 288 to the flush line 236. When the valve 292 is opened to the flush line 236 a pressurized source of fluid is provided. In an implementation, the valve 292 is coupled via a mechanical or electromechanical coupler 295 to the aspiration source 600 such that the valve 292 is only open when the aspiration source 600 is on. Alternately, the valve 292 is coupled to a flow sensor 275 in the aspiration line 230, such that the valve 292 is only on when there is flow in the direction towards the aspiration source 600. In these implementations, the flow rate of the flush source 288 is configured to flow just enough to keep the proximal extension 240 clear of blood but not so high as to cause flow to work against the aspiration flow and limit aspiration of thrombus. An advantage of this implementation is that the proximal extension 240 remains clear of blood and any emboli or air that is in the proximal extension 240 is clearly visible. This provides a feedback to the user on when and if to flush the catheter with saline or contrast via syringe 286.


In another implementation, the valve 292 is coupled either mechanically or electromechanically to the valve 242 that connects the sheath body 222 to the proximal portion 240 of the sheath 220. The coupling 290 can be configured such that the valve 292 can only be opened when the valve 242 is closed. This feature allows the proximal extension 240 to be cleared of blood via a flush step, without risk of flushing emboli back through the catheter into the vasculature. The coupling 290 may be configured in one of several ways For example, the coupling 290 may always open the valve 238 when the valve 242 is closed, or the coupling may prevent the valve 238 from opening unless valve 242 is closed but that does not automatically open.


In an implementation, the valve 292 is a variable state valve that allows different levels of flush flow rate. In this example, the valve 292 is configured to allow a slow flush when the aspiration source is on a low setting, a higher level of flush when the aspiration source is on a high setting. In an implementation, the valve allows yet a higher level of flush when the valve 242 is closed. These configurations allow a continuous removal of debris and/or clear visibility of the proximal portion of the access sheath and minimizes the risk of distal emboli or air entering the vasculature during the steps of the procedure. For example, during the step when the distal tip of catheter is being removed from the proximal hemostasis valve 234, any clot that was captured on the tip of the catheter may be liberated when the catheter is pulled through the valve, but with the continuous flush the liberated emboli would be flushed into the aspiration line and not remain in the sheath where it might be re-injected into the vasculature, for example during a contrast injection after the catheter is removed.


Again with respect to FIG. 1, the system 100 may include a kit of multiple devices. In an implementation, the kit includes an access sheath system 200 wherein the access sheath system includes an access sheath, one or more tapered sheath dilators, and one or more sheath guidewires. In another implementation, the system 100 includes an access sheath system 200 and one or more spined catheter systems 300 with one or more inner diameters. In an implementation, the spined catheter system 300 includes a spined aspiration catheter 320 and a tapered dilator 340. In an implementation, the spined catheter system 300 also includes a catheter clearing tool 350. In yet another implementation, the system 100 includes an access sheath system 200, a tapered catheter system 300, a microcatheter 400, and a retrievable stent device 500.


In an implementation configured for transcarotid access, the kit includes an access sheath 220, wherein the insertable sheath body 222 length is about 23 cm, the proximal extension 240 is about 22 cm, the connector 226 is about 7 cm and the proximal hemostasis valve 234 is about 5 cm, for an overall access sheath length of about 57 cm. In an implementation, the kit also includes a spined aspiration catheter 320 wherein the catheter distal luminal portion 322 is about 20 cm, the transition section 326 is about 2-4 cm, and the spine section 330 is about 65 cm, for an overall spined catheter length of about 88 cm. In another implementation, the kit also includes a tapered dilator 340 with a working length of 93 cm. In another implementation, the kit also includes a microcatheter 400 with a working length of about 198 cm and a retrievable stent device 500 with an overall length of 128 cm.


In an implementation configured for transfemoral access, the kit includes an access sheath system 220, wherein the insertable sheath body 222 length is about 90 cm, the proximal extension 240 is about 22 cm, the connector 226 is about 7 cm and the proximal hemostasis valve 234 is about 5 cm, for an overall access sheath length of about 124 cm. The proximal portion of the access sheath may be a removable proximal portion 280. In an implementation, the kit also includes a spined aspiration catheter 320, wherein the catheter distal luminal portion 322 is about 20 cm, the transition section 326 is about 2-4 cm, the spine section 330 is about 132 cm, for an overall spined catheter length of about 155 cm. In another implementation, the kit also includes a tapered dilator 340 with a working length of 160 cm. In another implementation, the kit also includes a microcatheter 400 with a working length of about 165 cm and a retrievable stent device 500 with an overall length of 195 cm.


In another implementation, the kit includes an access sheath 220 with a removable proximal portion 280, and a single lumen aspiration catheter. In another implementation, the kit includes only the proximal portion 280 that can be attached to any introducer sheath suitable for the procedure. In this implementation, the kit may also include a spined aspiration catheter 320 or a single lumen aspiration catheter.


In any of these implementations, the kit may also include an aspiration source, for example a pump, an attachment to a vacuum pump, a syringe, a syringe that is attachable to a syringe pump, or the like. The kit may also include means for automatic flushing, for example coupling means 290 or 292.


As described elsewhere herein, it should be appreciated that reference to one implementation of an access sheath system or catheter system is not intended to be limited and that the kits described herein can incorporate any of the systems and/or ancillary devices described herein as having any of a variety of features. For example, where an access sheath is described as being a part of a kit it should be appreciated that one or more features of any of the access sheaths or access sheath systems described herein can be incorporated. Similarly, where a spined catheter is described as being part of a kit one or more featured of any of the spined catheters or spined catheter systems described herein can be incorporated.



FIGS. 2A and 3 illustrates methods of use. As shown in FIG. 2A, an access sheath 220 is inserted using standard vascular access sheath into the femoral artery, and advanced until the sheath tip is positioned at a site as distal as safely possible in the internal or common carotid artery. In FIG. 3, the access sheath 220 is inserted directly into the common carotid artery, and advanced until the sheath tip is positioned at a site as distal as safely possible in the internal carotid artery. In either scenario, the sheath may be advanced initially to the common carotid artery or proximal internal carotid artery, and then the dilator and is exchanged for a softer dilator before advancing the sheath more distally into the internal carotid artery. The sheath is then secured to the patient using a suture through the eyelet on the sheath connector. The sheath aspiration line 230 is connected to an aspiration source 600 such as a syringe or aspiration pump. The sheath aspiration line may also be connected via a stopcock or stopcock manifold to a forward flush line (such as a pressurized saline bag).


Once the sheath tip is positioned at the desired location, it is secured to the patient. A spined catheter, tapered dilator, and guidewire are pre-assembled in a co-axial configuration and introduced through the sheath proximal hemostasis valve into the carotid artery. The spined aspiration catheter 320 is advanced through access sheath and positioned until the distal tip is at the treatment site. The devices are advanced using standard interventional techniques until the distal catheter tip is at the proximal face of the occlusion. A mark 332 on the spine 330 ensures that there is still an overlap region 120 between the distal luminal portion 322 of the catheter and the access sheath body 222. At this point, the tapered dilator 340 and guidewire can be removed. In an alternate implementation, a microcatheter 400 is used in place of the tapered dilator 340 to help navigate the catheter 320 to the occlusion. During the procedure, the forward flush is opened to the aspiration lumen to keep the lumen clear before or between periods of aspiration. At any point during device navigation, aspiration may be initiated from the aspiration source 600 at a level suitable for distal embolic protection, for example when the guidewire or microcatheter 400 is crossing the occlusion.


Once the distal tip of the spined aspiration catheter 320 is at the face of the clot, aspiration is initiated at a level suitable for aspiration thrombectomy, which is a higher level than for distal embolic protection. The catheter 320 may remain in aspiration mode against the clot for some period of time, as deemed suitable by the user. Depending on the results of the aspiration thrombectomy maneuver (as observed by flow though the aspiration line and/or resistance to backwards force on the spine of the catheter), the user may determine that the clot has been completely aspirated, or if not, the user may choose to move the catheter 320 back and forth to aspirate the clot in situ, or to slowly retract the catheter 320 into the sheath 220. If flow is restored to the artery via aspiration of the clot through the catheter 320 and sheath 220, a final angiogram may be performed and the catheter 320 can be retracted. If however, thrombus occludes the catheter tip and cannot be removed, the catheter 320 is pulled back, with some or all of the occlusion attached through suction force to the tip of the catheter 320.


In the latter scenario, aspiration is maintained at the tip of the catheter 320 the entire time the catheter 320 is being pulled into the access sheath 220. Once the catheter 320 has been completely retracted into the access sheath 220, the catheter 320 can be quickly removed from the sheath body 222 while aspiration is maintained on the sheath 220. It should be appreciated that the catheter 320 may be withdrawn into the sheath body 222 after extending through the distal opening 219 at the distal tip of the sheath body 222. Alternatively, the catheter 320 may be extending through a side opening 219 near a distal end region of the sheath body 222 such that withdrawal of the catheter 320 into the sheath body 220 occurs through this side opening 219. At some time during catheter retraction, depending on if the catheter 320 is clogged with occlusive material, the aspiration level may be changed from a high level desirable for aspiration thrombectomy to a lower level desirable for distal embolic protection. By providing the ability to maintain aspiration continuously from either the catheter tip or the sheath tip or the sheath distal region, and providing the means to change aspiration levels and maintain asp, the procedure optimizes the ability to aspiration clot while minimizing distal emboli and minimizing blood loss from aspiration. If desired, aspiration may also be initiated at the flush line 236 of the proximal valve 234, to reduce chance of distal embolization during removal of the catheter tip with possibly adhered clot through the proximal valve 234.


The spined aspiration catheter 320 may be removed completely from the proximal hemostasis valve 234 of the sheath 220. Alternately, if the access sheath 220 has a proximal extension 240, the distal luminal portion 322 may be pulled into the proximal extension portion 240. In the latter scenario, once pulled in, the catheter 320 and sheath 220 may be flushed to remove potential embolic material without removing the catheter 320 completely from the sheath 220. A vigorous flush from the proximal valve flush line 236 simultaneous with aspiration from the aspiration line 230 creates a flush environment for the catheter 320 and sheath 220. If desired, a catheter clearing tool 350 may be inserted into the sheath proximal valve 234 and used at this time to clear the inner lumen 323 of the catheter 320. If the access sheath 220 has a connector valve 242, the proximal portion 240 may be closed off from the sheath body 222 during this stage, so that there is no risk of flushing embolic material into the sheath body 222 and thence into the artery.


Alternately, the valve 242 may be closed off and aspiration paused while the proximal valve 242 is opened or removed and the catheter 320 is completely removed from the sheath 220. Closing the valve 242 limits the blood loss from the sheath 220 as the catheter 320 is removed. The catheter 320 may then be flushed onto the table or into a bowl or other receptacle, using the cleaning tool 350. The proximal extension portion 240 may also be flushed by providing a flush source 288 from the proximal valve flush line 236 simultaneous with aspiration from the aspiration line 230, or by opening a side port on the aspiration line 230 to flush to the table or into a bowl or other receptacle. If desired, an angiogram may be performed to assess flow through the treated artery. If the procedure dictates, the catheter 320 or another catheter may be re-advanced as above over a guidewire and tapered dilator 340 or microcatheter 400 to the site of the occlusion to attempt another aspiration thrombectomy step. The flushing of the catheters and proximal extension portion 240 of the access sheath 220 minimizing the risk of distal emboli during these subsequent steps.


In another exemplary method, a retrievable stent device 500 can be used in conjunction with aspiration to remove the thrombotic occlusion. FIG. 9 illustrates this method of use through either a transcarotid or transfemoral access site. In this scenario, the access sheath 220 can be positioned as above and advanced until the sheath tip is positioned at a site as distal as safely possible in the internal carotid artery. The spined aspiration catheter 320 can be then pre-loaded onto a microcatheter 400 and guidewire, and the co-axial assembly can be introduced via the access sheath 220 into the carotid artery and advanced into the cerebral vasculature. The microcatheter 400 and guidewire can be advanced across occlusion. The tip of the spined aspiration catheter 320 can be advanced as distal as possible but proximal to the clot.


At this point, the guidewire can be removed and the retrievable stent device 500 inserted through the microcatheter 400 until it too is positioned across the occlusion. The microcatheter 400 can be pulled back to deploy the stent. At any point during device navigation, aspiration may be initiated from the aspiration source at a level suitable for distal embolic protection, for example when the guidewire or microcatheter 400 is crossing the occlusion, or prior to stent deployment. By having aspiration initiated before stent deployment, any emboli that was liberated while crossing the lesion is not carried downstream on restoration of flow in the artery, but is rather captured into the catheter tip. While the retrievable stent device 500 is deployed, aspiration may be maintained. It is typically deployed for several minutes before retraction of the stent is attempted, to maximize the engagement of the stent struts to the occlusion. Then, the retrievable stent device 500 can be pulled into the spined catheter 320 and continued to be retracted until it has been completely removed from the proximal valve of the access sheath 220.


Alternately, the stent device 500 can be pulled into the distal portion of the spined catheter 320, and the stent device 500 and spined catheter 320 can be pulled back together out of the access sheath 220. Aspiration may be increased to a higher level during stent and/or catheter retraction steps, to optimize aspiration of clot and minimize distal emboli. If the access sheath 220 has a proximal extension 240 with a valve on the connector, the device 500 can be pulled into the proximal extension 240 and the valve closed, and then the proximal hemostasis valve 234 may be opened widely and the stent device 500 or the stent device/spined catheter combination may be pulled out. The proximal extension section 240 may then be flushed via the valve flush line 236 and the aspiration line 230 before the same or alternate devices are reinserted for another thrombectomy attempt, if the procedure dictates.


Alternately after placement of an aspiration catheter 320, a long or segmented stent retriever 500 can be positioned as above with a microcatheter 400 such that part of the expandable portion 510 is across the thrombus and part is in the distal segment 322 of the catheter 320, and then expanded. After the expandable portion 510 is expanded aspiration can be initiated so that thrombus either is suctioned completely out of the vessel and catheter 320 into the aspiration source 600, or is suctioned into the distal tip and/or distal lumen 323 of the catheter 320. At that point, the long or segmented stent retriever 500 can be carefully pulled into the catheter 320, while maintaining aspiration. During this time clot that has been clogging the catheter 320 and/or debris that is liberated during this step should be aspirated into the catheter 320. Complete removal of the stent retrieval device 500 from the working channel 323 of the catheter 320 should free up the lumen 323 from occlusive material.


In any of these scenarios, the aspiration source may be a variable or multi-state aspiration source that is configured to maximize the aspiration force on the thrombotic occlusion while minimizing blood loss during periods of free flow in the catheter.


In another exemplary method, the access sheath 220 has an occlusion balloon 246. As seen in FIG. 7, the balloon 246 may be inflated during steps of the procedure that are high risk for distal emboli, for example retraction of the stent device 500 or the spined catheter 320 with adhered clot. The balloon 246 has the effect of stopping antegrade flow and increasing the force of aspiration in the carotid artery, thus increasing the aspiration of clot and reducing the risk of distal emboli.


In another exemplary method, the access sheath 220 has an expandable distal tip. In this method, the distal tip may be expanded sometime after the access sheath tip has been positioned at the desired site, but before retraction of the spined catheter 320 into the access sheath 220. This method would reduce the chance of distal emboli caused by the release of clot that was adhered to the distal tip of the spined catheter 320, as the distal tip is pulled into the tip of the sheath 220. Instead, the access sheath tip that is expanded or flared out acts as a funnel to capture the entire clot.


In another exemplary method and as discussed briefly above, the access sheath 1220 has a side opening 1219 (best shown in FIG. 12C). In this method, the spined catheter 1320 having a spined dilator 1340 extending through lumen 1323 of the distal luminal portion 1322 of the catheter 1320 can be advanced distally through the lumen 1223 of the access sheath 1220 towards the distal end region of the sheath body 1222. The distal tip of the distal luminal portion 1322 of the spined catheter 1320 (which may having the spined dilator extending through the distal luminal portion 1322 and forming a distal-most end to the catheter system) may exit the lumen 1223 via the side opening 1219 and then be further advanced distally beyond the distal tip of the access sheath 1220. A ramp feature 1217 or other internal feature can be incorporated at a distal end region of the lumen 1223 to provide a surface against which the tip of the dilator can be deflected to guide the catheter 1320 away from a longitudinal axis A of the lumen 1223 of the sheath body 1222 towards the side opening 1219 to achieve a smooth transition or exit from the lumen 1223. The distal tip 1346 of the dilator 1340 can abut against the ramp feature 1217 and be directed at a slight angulation away from the longitudinal axis of the sheath body 1222 towards the side opening 1219. As described elsewhere herein, the sheath body 1222 and thus the side opening 1219 can be rotated around the longitudinal axis A such that the one or more side openings 1219 are positioned to allow for distal extension of the catheter 1320 from the side openings 1219 in a desired direction relative to the longitudinal axis A of the sheath 1220. This will often be dictated by the anatomy encountered by the operator. Also as mentioned elsewhere herein, an overlap region 1120 is formed between the distal luminal portion 1322 of the catheter and the access sheath body 1222. A sealing element 1336 can be positioned on the external surface of the distal luminal portion 1322, for example, near a proximal end region of the distal luminal portion 1322 and may be located within the overlap region 1120. The seal formed can allow for full transmission of aspiration force through the contiguous lumen formed by the lumen 1323 of the luminal portion 1322 and the lumen 1223 of the access sheath body 1222 upon withdrawal of the dilator 1340 from the lumen 1323 of the luminal portion 1322.


In another exemplary method, the aspiration source 600 is connected to a blood collection reservoir that maintains the integrity of the blood in such a way that the blood can be safely returned to the patient at the conclusion of the thrombectomy portion of the procedure, either directly or through subsequent treatment of the blood such as cell washing and/or blood filtration. In another exemplary method, the aspiration source is connected to a blood shunt that is connected in turn to a device such as a venous sheath or a venous return catheter that enables blood to be returned to the patient during the procedure and not requiring a blood reservoir. In another exemplary method, the blood is collected in a reservoir and subsequently discarded at the end of the procedure.


In another exemplary method, the access sheath 1220 is delivered as described elsewhere herein from a femoral insertion site to a right or left subclavian artery or an external carotid artery. The access sheath 1220 may be delivered to a carina of a bifurcation between a target vessel having the embolus, such as the internal carotid artery (ICA), and another vessel, such as the external carotid artery (ECA). Once the access sheath 1220 is in position a working device such as a splined aspiration catheter 1320 can be delivered through the lumen 1223 of the access sheath 1220 into the target vessel. The lumen 1223 of the access sheath 1220 and the lumen 1323 of the catheter 1320 are contiguous and form a stepped up diameter for aspiration as described elsewhere herein. An overlap region 1120 is maintained between the catheter 1320 extending distally from the lumen 1223 of the access sheath 1220. It should be appreciated that the catheter 1320 can extend distally from the lumen 1223 of the access sheath 1220 through an opening 1221 at the distal tip of the access sheath 1220 or a side opening 1119 near the distal region of the access sheath 1220. The body 1222 of the access sheath 1220 may be oriented to provide optimum placement of the side opening 1119 relative to the anatomy. The overlap region 1120 between the distal luminal portion 1322 of the catheter 1320 and the access sheath body 1222 can create a seal and allow for full transmission of aspirating force through the contiguous lumen formed by the lumen 1323 of the luminal portion 1322 and the lumen 1223 of the access sheath body 1222, as well as providing a seal for delivery of fluids to the target vessel such as angiographic contrast injection, saline, one or more drugs or other materials directly into the neurovascular anatomy. The spined aspiration catheter 1320 can create a more powerful aspiration force by allowing for the working lumen 1223 of the access sheath 1220 to provide a majority of the aspiration column. As described elsewhere herein, the dimension of the lumen 1323 of the distal luminal portion 1322 of the aspiration catheter 1320 may be less than the diameter of the lumen 1223 of the access sheath 1220, which is reduced only by a diameter of the spine 1330 extending therethrough. The increased diameter of the lumen can create a larger aspiration column than, e.g., an aspiration column of a large bore catheter having a similar overall length. The spined aspiration catheter 1320 may also be used as a supportive delivery catheter, for example, where the operator wants to reach the petrous carotid or other hard to reach landmarks within the cerebral vasculature. More particularly, after delivering the spined aspiration catheter 1320 into the target vessel through the working lumen 1223 of the access sheath 1220, a secondary working device such as a guidewire, microcatheter, stent retriever, etc. may be delivered through the lumen 1323 into a more distal anatomy to perform other procedural operations as described elsewhere herein.


While this specification contains many specifics, these should not be construed as limitations on the scope of an invention that is claimed or of what may be claimed, but rather as descriptions of features specific to particular implementations. Certain features that are described in this specification in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results. Therefore the spirit and scope of the appended claims should not be limited to the description of the implementations contained herein.

Claims
  • 1. A method for performing a medical procedure in a cerebral vessel of a patient, the method comprising: inserting an access sheath into a patient through a transfemoral access site, the access sheath having a proximal end with a hub, a distal end, and a lumen extending therebetween;inserting a system of devices through the access sheath, the system of devices comprising: a first catheter comprising: a flexible distal luminal portion having a proximal end, a distal end, and a single lumen extending between the proximal and distal ends of the flexible distal luminal portion of the first catheter, anda proximal elongate body configured to control movement of the first catheter and extending proximally from a point of attachment adjacent the proximal end of the flexible distal luminal portion of the first catheter, wherein an outer diameter of the proximal elongate body of the first catheter at the point of attachment of the first catheter is smaller than an outer diameter of the proximal end of the flexible distal luminal portion of the first catheter; anda second catheter comprising: a flexible distal luminal portion having a proximal end, a distal end, and a single lumen extending between the proximal end of the flexible distal luminal portion of the second catheter and the distal end of the flexible distal luminal portion of the second catheter, anda proximal elongate body configured to control movement of the second catheter and extending proximally from a point of attachment adjacent the proximal end of the flexible distal luminal portion of the second catheter, wherein an outer diameter of the proximal elongate body of the second catheter at the point of attachment of the second catheter is smaller than an outer diameter of the proximal end of the flexible distal luminal portion of the second catheter;advancing the system of devices through an internal carotid artery from the transfemoral access site of the patient, andapplying aspiration to a contiguous aspiration lumen formed by the single lumen of the second catheter fluidly communicating with the single lumen of the first catheter which fluidly communicates with the lumen of the access sheath.
  • 2. The method of claim 1, wherein the first catheter is sized to be slidably received within the lumen of the access sheath such that an outer diameter of the first catheter seals with the lumen of the access sheath, and the second catheter is sized to be slidably disposed within the single lumen of the first catheter, such that an outer diameter of the second catheter seals with the single lumen of the first catheter.
  • 3. The method of claim 1, wherein the first catheter and the second catheter are nested and advanced to allow for extended reach in the cerebral vasculature.
  • 4. The method of claim 1, wherein inserting the system of devices through the access sheath comprises advancing the first and second catheters through a single rotating hemostasis valve detachably attached to the hub and into the lumen of the access sheath so that the proximal elongate bodies of the first and second catheters pass through an opening of the rotating hemostasis valve into the lumen of the access sheath.
  • 5. The method of claim 1, further comprising advancing the first catheter relative to the access sheath forming an overlap region adjacent the proximal end of the flexible distal luminal portion of the first catheter.
  • 6. The method of claim 5, further comprising advancing the second catheter relative to the first catheter forming an overlap region adjacent the proximal end of the flexible distal luminal portion of the second catheter.
  • 7. The method of claim 1, wherein a difference between at least a portion of the outer diameter of the proximal end of the first catheter and the lumen of the access sheath is configured to provide sealing sufficient to transmit aspiration force.
  • 8. The method of claim 7, wherein the difference is less than 0.002 inch.
  • 9. The method of claim 1, wherein the proximal elongate body of the first catheter is less flexible than the flexible distal luminal portion of the first catheter, and wherein the proximal elongate body of the second catheter is less flexible than the flexible distal luminal portion of the second catheter.
  • 10. The method of claim 1, further comprising advancing the first catheter towards an embolus within a cerebral blood vessel.
  • 11. The method of claim 10, further comprising extending the distal end of the flexible distal luminal portion of the second catheter beyond the distal end of the flexible distal luminal portion of the first catheter towards the embolus.
  • 12. The method of claim 11, wherein applying aspiration to the contiguous aspiration lumen comprises initiating aspiration after the distal end of the flexible distal luminal portion of the second catheter is at a face of the embolus.
  • 13. The method of claim 12, further comprising moving the second catheter back and forth to aspirate the embolus in situ.
  • 14. The method of claim 12, further comprising retracting the second catheter relative to the access sheath while applying aspiration to the contiguous aspiration lumen.
  • 15. The method of claim 14, wherein retracting the second catheter comprises withdrawing the embolus occluding the distal end of the flexible distal luminal portion of the second catheter.
  • 16. The method of claim 15, wherein withdrawing the embolus occluding the distal end of the flexible distal luminal portion of the second catheter comprises withdrawing the embolus into the first catheter.
  • 17. The method of claim 15, wherein withdrawing the embolus occluding the distal end of the flexible distal luminal portion of the second catheter comprises withdrawing the embolus into the access sheath.
  • 18. The method of claim 1, further comprising advancing an interventional device out the distal end of the flexible distal luminal portion of the second catheter, wherein the interventional device is a snare, coil, stent, guidewire, or microcatheter.
  • 19. The method of claim 1, further comprising an inner member extending through the single lumen of the second catheter, wherein the inner member comprises a lumen and a tapered distal end that extends distal to the distal end of the flexible distal luminal portion of the second catheter.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/543,215, filed Aug. 16, 2019, now U.S. Pat. No. 11,383,064, issued Jul. 12, 2022 which is a continuation of Ser. No. 15/856,979, filed Dec. 28, 2017, now U.S. Pat. No. 10,456,555, issued Oct. 29, 2019, which is a continuation of U.S. application Ser. No. 15/805,673, filed Nov. 7, 2017, now U.S. Pat. No. 10,485,952, issued Nov. 26, 2019, which is a continuation of U.S. application Ser. No. 15/015,799, filed Feb. 4, 2016, now U.S. Pat. No. 9,820,761, issued Nov. 21, 2017, which claims priority to U.S. Provisional Application Ser. No. 62/111,481, filed Feb. 4, 2015, and U.S. Provisional Application Ser. No. 62/142,637, filed Apr. 3, 2015, the disclosures are each incorporated by reference herein in their entireties. This application is also related to the following U.S. Patent Applications, which are incorporated by reference in their entirety: (1) U.S. patent application Ser. No. 14/576,953, filed Dec. 19, 2014, now U.S. Pat. No. 9,561,345, issued on Feb. 7, 2017; and (2) U.S. patent application Ser. No. 14/569,365, filed Dec. 12, 2014, now U.S. Pat. No. 9,265,512, issued on Feb. 23, 2016; (3) U.S. patent application Ser. No. 14/537,316, filed Nov. 10, 2014, now U.S. Pat. No. 9,241,699, issued on Jan. 26, 2016; (4) U.S. patent application Ser. No. 14/221,917, filed Mar. 21, 2014, now U.S. Pat. No. 9,693,789, issued on Jul. 4, 2017, which are all incorporated by reference.

US Referenced Citations (1072)
Number Name Date Kind
2623520 Bamford, Jr. et al. Dec 1952 A
2730101 Hoffman Jan 1956 A
3612050 Sheridan Oct 1971 A
3631848 Muller Jan 1972 A
3949757 Sabel Apr 1976 A
3996938 Clark, III Dec 1976 A
4013080 Froning Mar 1977 A
4020829 Willson et al. May 1977 A
4033331 Guss et al. Jul 1977 A
4174715 Hasson Nov 1979 A
4319580 Colley et al. Mar 1982 A
4323071 Simpson et al. Apr 1982 A
4406656 Hattler et al. Sep 1983 A
4571240 Samson et al. Feb 1986 A
4610662 Weikl et al. Sep 1986 A
4619263 Frisbie et al. Oct 1986 A
4676249 Arenas et al. Jun 1987 A
4723549 Wholey et al. Feb 1988 A
4728319 Masch Mar 1988 A
4739768 Engelson Apr 1988 A
4762128 Rosenbluth Aug 1988 A
4771777 Horzewski et al. Sep 1988 A
4784636 Rydell Nov 1988 A
4790812 Hawkins, Jr. et al. Dec 1988 A
4794928 Kletschka Jan 1989 A
4795434 Kujawski Jan 1989 A
4799496 Hargreaves et al. Jan 1989 A
4834709 Banning et al. May 1989 A
4840690 Melinyshyn et al. Jun 1989 A
4863431 Vaillancourt Sep 1989 A
4865581 Lundquist et al. Sep 1989 A
4873978 Ginsburg Oct 1989 A
4873979 Hanna Oct 1989 A
4883460 Zanetti Nov 1989 A
4887613 Farr et al. Dec 1989 A
4898575 Fischell et al. Feb 1990 A
4900303 Lemelson Feb 1990 A
4921478 Solano et al. May 1990 A
4921479 Grayzel May 1990 A
4921484 Hillstead May 1990 A
4923462 Stevens May 1990 A
4946440 Hall Aug 1990 A
4946443 Hauser et al. Aug 1990 A
4994033 Shockey et al. Feb 1991 A
4994067 Summers Feb 1991 A
4998919 Schnepp-Pesch et al. Mar 1991 A
5011488 Ginsburg Apr 1991 A
5011490 Fischell et al. Apr 1991 A
5053008 Bajaj Oct 1991 A
5059178 Ya Oct 1991 A
5102415 Guenther et al. Apr 1992 A
5103827 Smith Apr 1992 A
5108419 Reger et al. Apr 1992 A
5135484 Wright Aug 1992 A
5152277 Honda et al. Oct 1992 A
5161534 Berthiaume Nov 1992 A
5163906 Ahmadi Nov 1992 A
5185004 Lashinski Feb 1993 A
5188621 Samson Feb 1993 A
5200248 Thompson et al. Apr 1993 A
5207648 Gross May 1993 A
5211651 Reger et al. May 1993 A
5217705 Reno et al. Jun 1993 A
5219332 Nelson et al. Jun 1993 A
5243997 Uflacker et al. Sep 1993 A
5250060 Carbo et al. Oct 1993 A
5257979 Jagpal Nov 1993 A
5267960 Hayman et al. Dec 1993 A
5269297 Weng et al. Dec 1993 A
5303714 Abele et al. Apr 1994 A
5308318 Plassche, Jr. May 1994 A
5312338 Nelson et al. May 1994 A
5312356 Engelson et al. May 1994 A
RE34633 Sos et al. Jun 1994 E
5318032 Lonsbury et al. Jun 1994 A
5324262 Fischell et al. Jun 1994 A
5325868 Kimmelstiel Jul 1994 A
5328471 Slepian Jul 1994 A
5338300 Cox Aug 1994 A
5352197 Hammersmark et al. Oct 1994 A
5364358 Hewitt et al. Nov 1994 A
5370623 Kreamer Dec 1994 A
5380284 Don Michael Jan 1995 A
5385562 Adams et al. Jan 1995 A
5392778 Horzewski Feb 1995 A
5395383 Adams et al. Mar 1995 A
5413575 Haenggi May 1995 A
5423331 Wysham Jun 1995 A
5429605 Richling et al. Jul 1995 A
5437632 Engelson Aug 1995 A
5438993 Lynch et al. Aug 1995 A
5441051 Hileman et al. Aug 1995 A
5443454 Tanabe et al. Aug 1995 A
5454795 Samson Oct 1995 A
5465716 Avitall Nov 1995 A
5466222 Ressemann et al. Nov 1995 A
5476450 Ruggio Dec 1995 A
5484407 Osypka Jan 1996 A
5484412 Pierpont Jan 1996 A
5484418 Quiachon et al. Jan 1996 A
5485667 Kleshinski Jan 1996 A
5490859 Mische et al. Feb 1996 A
5492530 Fischell et al. Feb 1996 A
5496294 Hergenrother et al. Mar 1996 A
5501694 Ressemann et al. Mar 1996 A
5522836 Palermo Jun 1996 A
5527292 Adams et al. Jun 1996 A
5533967 Imran Jul 1996 A
5538512 Zenzon et al. Jul 1996 A
5542936 Razi Aug 1996 A
5542937 Chee et al. Aug 1996 A
5546958 Thorud et al. Aug 1996 A
5549119 Solar Aug 1996 A
5549601 McIntyre et al. Aug 1996 A
5549626 Miller et al. Aug 1996 A
5558635 Cannon Sep 1996 A
5571122 Kelly et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5578009 Kraus et al. Nov 1996 A
5591194 Berthiaume Jan 1997 A
5599307 Bacher et al. Feb 1997 A
5599326 Carter Feb 1997 A
5628754 Shevlin et al. May 1997 A
5643254 Scheldrup et al. Jul 1997 A
5658263 Dang et al. Aug 1997 A
5658264 Samson Aug 1997 A
5658309 Berthiaume et al. Aug 1997 A
5662622 Gore et al. Sep 1997 A
5693029 Leonhardt Dec 1997 A
5695483 Samson Dec 1997 A
5702373 Samson Dec 1997 A
5702439 Keith et al. Dec 1997 A
5707376 Kavteladze et al. Jan 1998 A
5720764 Naderlinger Feb 1998 A
5730734 Adams et al. Mar 1998 A
5749849 Engelson May 1998 A
5749858 Cramer May 1998 A
5766191 Trerotola Jun 1998 A
5776141 Klein et al. Jul 1998 A
5776142 Gunderson Jul 1998 A
5794629 Frazee Aug 1998 A
5795341 Samson Aug 1998 A
5810869 Kaplan et al. Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5817101 Fiedler Oct 1998 A
5827229 Auth et al. Oct 1998 A
5827242 Follmer et al. Oct 1998 A
5833650 Imran Nov 1998 A
5836868 Ressemann et al. Nov 1998 A
5836926 Peterson et al. Nov 1998 A
5836955 Buelna et al. Nov 1998 A
5843002 Pecor et al. Dec 1998 A
5843051 Adams et al. Dec 1998 A
5843103 Wulfman Dec 1998 A
5846251 Hart Dec 1998 A
5851189 Forber Dec 1998 A
5851210 Torossian Dec 1998 A
5853400 Samson Dec 1998 A
5876367 Kaganov et al. Mar 1999 A
5876386 Samson Mar 1999 A
5882329 Patterson et al. Mar 1999 A
5882334 Sepetka et al. Mar 1999 A
5885209 Green Mar 1999 A
5891114 Chien et al. Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5899890 Chiang et al. May 1999 A
5899892 Mortier et al. May 1999 A
5908407 Frazee et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911725 Boury Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5913848 Luther et al. Jun 1999 A
5916192 Nita et al. Jun 1999 A
5916208 Luther et al. Jun 1999 A
5921952 Desmond, III et al. Jul 1999 A
5928192 Maahs Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935122 Fourkas et al. Aug 1999 A
5935139 Bates Aug 1999 A
5938645 Gordon Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5957882 Nita et al. Sep 1999 A
5972019 Engelson et al. Oct 1999 A
5976093 Jang Nov 1999 A
5976178 Goldsteen et al. Nov 1999 A
5997508 Lunn et al. Dec 1999 A
5997523 Jang Dec 1999 A
5997557 Barbut et al. Dec 1999 A
6004310 Bardsley et al. Dec 1999 A
6007530 Domhofer et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6013085 Howard Jan 2000 A
6022336 Zadno-Azizi et al. Feb 2000 A
6022340 Sepetka et al. Feb 2000 A
6030349 Wilson et al. Feb 2000 A
6030369 Engelson et al. Feb 2000 A
6033388 Nordstrom et al. Mar 2000 A
6044845 Lewis Apr 2000 A
6053903 Samson Apr 2000 A
6053904 Scribner et al. Apr 2000 A
6066149 Samson et al. May 2000 A
6071263 Kirkman Jun 2000 A
6074357 Kaganov et al. Jun 2000 A
6074398 Leschinsky Jun 2000 A
6090072 Kratoska et al. Jul 2000 A
6090118 McGuckin, Jr. Jul 2000 A
6106530 Harada Aug 2000 A
6110139 Loubser Aug 2000 A
6117141 Ouchi Sep 2000 A
6120480 Zhang et al. Sep 2000 A
6135991 Muni et al. Oct 2000 A
6139524 Killion Oct 2000 A
6142958 Hammarstrom et al. Nov 2000 A
6142987 Tsugita Nov 2000 A
6146370 Barbut Nov 2000 A
6146373 Cragg et al. Nov 2000 A
6146396 Konya et al. Nov 2000 A
6146415 Fitz Nov 2000 A
6152909 Bagaoisan et al. Nov 2000 A
6152912 Jansen et al. Nov 2000 A
6156005 Theron Dec 2000 A
6159195 Ha et al. Dec 2000 A
6159230 Samuels Dec 2000 A
6161547 Barbut Dec 2000 A
6165163 Chien et al. Dec 2000 A
6165167 Delaloye Dec 2000 A
6165199 Barbut Dec 2000 A
6168579 Tsugita Jan 2001 B1
6171295 Garabedian et al. Jan 2001 B1
6176844 Lee Jan 2001 B1
6197016 Fourkas et al. Mar 2001 B1
6203561 Ramee et al. Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210370 Chi-Sing et al. Apr 2001 B1
6221038 Brisken Apr 2001 B1
6221049 Selmon et al. Apr 2001 B1
6228046 Brisken May 2001 B1
6228052 Pohndorf May 2001 B1
6234971 Jang May 2001 B1
6238402 Sullivan, III et al. May 2001 B1
6238412 Dubrul et al. May 2001 B1
6238430 Klumb et al. May 2001 B1
6240231 Ferrera et al. May 2001 B1
6254628 Wallace et al. Jul 2001 B1
6258052 Milo Jul 2001 B1
6258080 Samson Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6270477 Bagaoisan et al. Aug 2001 B1
6277115 Saadat Aug 2001 B1
6277139 Levinson et al. Aug 2001 B1
6287319 Aboul-Hosn et al. Sep 2001 B1
6295989 Connors, III Oct 2001 B1
6295990 Lewis et al. Oct 2001 B1
6306106 Boyle Oct 2001 B1
6306163 Fitz Oct 2001 B1
6309379 Willard et al. Oct 2001 B1
6346116 Brooks et al. Feb 2002 B1
6355027 Le et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364894 Healy et al. Apr 2002 B1
6364900 Heuser Apr 2002 B1
6368316 Jansen et al. Apr 2002 B1
6368338 Konya et al. Apr 2002 B1
6368344 Fitz Apr 2002 B1
6379325 Benett et al. Apr 2002 B1
6383172 Barbut May 2002 B1
6391044 Yadav et al. May 2002 B1
6394976 Winston et al. May 2002 B1
6413235 Parodi Jul 2002 B1
6423032 Parodi Jul 2002 B2
6423086 Barbut et al. Jul 2002 B1
6428531 Visuri et al. Aug 2002 B1
6435189 Lewis et al. Aug 2002 B1
6436087 Lewis et al. Aug 2002 B1
6451005 Saitou et al. Sep 2002 B1
6454741 Muni et al. Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6458151 Saltiel Oct 2002 B1
6464664 Jonkman et al. Oct 2002 B1
6468219 Njemanze Oct 2002 B1
6475195 Voda Nov 2002 B1
6475244 Herweck et al. Nov 2002 B2
6481439 Lewis et al. Nov 2002 B1
6482172 Thramann Nov 2002 B1
6482217 Pintor et al. Nov 2002 B1
6485466 Hamilton Nov 2002 B2
6485500 Kokish et al. Nov 2002 B1
6485501 Green Nov 2002 B1
6508824 Flaherty et al. Jan 2003 B1
6511470 Hamilton Jan 2003 B1
6511471 Rosenman et al. Jan 2003 B2
6514261 Randall et al. Feb 2003 B1
6514273 Voss et al. Feb 2003 B1
6517520 Chang et al. Feb 2003 B2
6524303 Garibaldi Feb 2003 B1
6527746 Oslund et al. Mar 2003 B1
6533800 Barbut Mar 2003 B1
6537241 Odland Mar 2003 B1
6537295 Petersen Mar 2003 B2
6540712 Parodi et al. Apr 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6551268 Kaganov et al. Apr 2003 B1
6551273 Olson et al. Apr 2003 B1
6551302 Rosinko et al. Apr 2003 B1
6554820 Wendlandt et al. Apr 2003 B1
6554827 Chandrasekaran et al. Apr 2003 B2
6555057 Barbut et al. Apr 2003 B1
6558377 Lee et al. May 2003 B2
6558405 McInnes May 2003 B1
6562049 Norlander et al. May 2003 B1
6562052 Nobles et al. May 2003 B2
6569148 Bagaoisan et al. May 2003 B2
6579246 Jacobsen et al. Jun 2003 B2
6579260 Maki et al. Jun 2003 B2
6579264 Rossi Jun 2003 B1
6579484 Tieman et al. Jun 2003 B1
6582390 Sanderson Jun 2003 B1
6582396 Parodi Jun 2003 B1
6582440 Brumbach Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6589262 Honebrink et al. Jul 2003 B1
6595953 Coppi et al. Jul 2003 B1
6595980 Barbut Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6605074 Zadno-Azizi et al. Aug 2003 B2
6610077 Hancock et al. Aug 2003 B1
6612999 Brennan et al. Sep 2003 B2
6616681 Hanson et al. Sep 2003 B2
6620148 Tsugita Sep 2003 B1
6623471 Barbut Sep 2003 B1
6623491 Thompson Sep 2003 B2
6623518 Thompson et al. Sep 2003 B2
6626886 Barbut Sep 2003 B1
6632236 Hogendijk Oct 2003 B2
6635070 Leeflang et al. Oct 2003 B2
6638243 Kupiecki Oct 2003 B2
6638245 Miller et al. Oct 2003 B2
6641573 Parodi Nov 2003 B1
6645160 Heesch Nov 2003 B1
6645222 Parodi et al. Nov 2003 B1
6652480 Imran et al. Nov 2003 B1
6656152 Putz Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6663652 Daniel et al. Dec 2003 B2
6673025 Richardson et al. Jan 2004 B1
6676637 Bonnette et al. Jan 2004 B1
6679893 Tran Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6685672 Forman Feb 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6689144 Gerberding Feb 2004 B2
6692473 St. Cyr et al. Feb 2004 B2
6695858 Dubrul et al. Feb 2004 B1
6695865 Boyle et al. Feb 2004 B2
6702782 Miller et al. Mar 2004 B2
6702834 Boylan et al. Mar 2004 B1
6706055 Douk et al. Mar 2004 B2
6711436 Duhaylongsod Mar 2004 B1
6716183 Clayman et al. Apr 2004 B2
6719717 Johnson et al. Apr 2004 B1
6723064 Babaev Apr 2004 B2
6726675 Beyar Apr 2004 B1
6730104 Sepetka et al. May 2004 B1
6733517 Collins May 2004 B1
6740104 Solar et al. May 2004 B1
6749627 Thompson et al. Jun 2004 B2
6755803 Le et al. Jun 2004 B1
6755812 Peterson et al. Jun 2004 B2
6755847 Eskuri Jun 2004 B2
6758854 Butler et al. Jul 2004 B1
6761708 Chiu et al. Jul 2004 B1
6764464 McGuckin, Jr. et al. Jul 2004 B2
6773448 Kusleika et al. Aug 2004 B2
6790204 Zadno-Azizi et al. Sep 2004 B2
6805684 Bonnette et al. Oct 2004 B2
6805692 Muni et al. Oct 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6824550 Noriega et al. Nov 2004 B1
6824553 Samson et al. Nov 2004 B1
6827730 Leschinsky Dec 2004 B1
6837881 Barbut Jan 2005 B1
6840949 Barbut Jan 2005 B2
6849068 Bagaoisan et al. Feb 2005 B1
6855136 Dorros et al. Feb 2005 B2
6866669 Buzzard et al. Mar 2005 B2
6878151 Carrison et al. Apr 2005 B2
6879854 Windheuser et al. Apr 2005 B2
6884235 McGuckin, Jr. et al. Apr 2005 B2
6902540 Dorros et al. Jun 2005 B2
6905490 Parodi Jun 2005 B2
6905505 Nash et al. Jun 2005 B2
6908474 Hogendijk et al. Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6926658 Farnan Aug 2005 B2
6929632 Nita et al. Aug 2005 B2
6929634 Dorros et al. Aug 2005 B2
6936060 Hogendijk et al. Aug 2005 B2
6945956 Waldhauser et al. Sep 2005 B2
6949104 Griffis et al. Sep 2005 B2
6951570 Linder et al. Oct 2005 B2
6958059 Zadno-Azizi Oct 2005 B2
6960189 Bates et al. Nov 2005 B2
6969395 Eskuri Nov 2005 B2
6972030 Lee et al. Dec 2005 B2
6977068 Nair et al. Dec 2005 B1
6991642 Petersen Jan 2006 B2
7001400 Modesitt et al. Feb 2006 B1
7004924 Brugger et al. Feb 2006 B1
7004931 Hogendijk Feb 2006 B2
7004952 Nobles et al. Feb 2006 B2
7022100 Aboul-Hosn et al. Apr 2006 B1
7029488 Schonholz et al. Apr 2006 B2
7033325 Sullivan Apr 2006 B1
7033336 Hogendijk Apr 2006 B2
7033344 Imran Apr 2006 B2
7037267 Lipson et al. May 2006 B1
7048758 Boyle et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7063714 Dorros et al. Jun 2006 B2
7083594 Coppi Aug 2006 B2
7104979 Jansen et al. Sep 2006 B2
7108677 Courtney et al. Sep 2006 B2
7115134 Chambers Oct 2006 B2
7115138 Renati et al. Oct 2006 B2
7118539 Vrba et al. Oct 2006 B2
7144386 Korkor et al. Dec 2006 B2
7150712 Buehlmann et al. Dec 2006 B2
7152605 Khairkhahan et al. Dec 2006 B2
7166088 Heuser Jan 2007 B2
7166120 Kusleika Jan 2007 B2
7169165 Belef et al. Jan 2007 B2
7172621 Theron Feb 2007 B2
7220271 Clubb et al. May 2007 B2
7223253 Hogendijk May 2007 B2
7229431 Houser et al. Jun 2007 B2
7229463 Sutton et al. Jun 2007 B2
7229464 Hanson et al. Jun 2007 B2
7232452 Adams et al. Jun 2007 B2
7235061 Tsugita Jun 2007 B2
7242977 Partridge et al. Jul 2007 B2
7250042 Kataishi et al. Jul 2007 B2
7306585 Ross Dec 2007 B2
7309334 von Hoffmann Dec 2007 B2
7316678 Nash et al. Jan 2008 B2
7329278 Seguin et al. Feb 2008 B2
7367982 Nash et al. May 2008 B2
7374560 Ressemann et al. May 2008 B2
7374561 Barbut May 2008 B2
7374564 Brown May 2008 B2
7381200 Katoh et al. Jun 2008 B2
7384412 Coppi Jun 2008 B2
7402151 Rosenman et al. Jul 2008 B2
7422579 Wahr et al. Sep 2008 B2
7449010 Hayase et al. Nov 2008 B1
7458980 Barbut Dec 2008 B2
7476232 Deal Jan 2009 B2
7497844 Spear et al. Mar 2009 B2
7507229 Hewitt et al. Mar 2009 B2
7524303 Don Michael et al. Apr 2009 B1
7534250 Schaeffer et al. May 2009 B2
7537568 Moehring May 2009 B2
7549974 Nayak Jun 2009 B2
7558622 Tran Jul 2009 B2
7604612 Ressemann et al. Oct 2009 B2
7625207 Hershey et al. Dec 2009 B2
7691121 Rosenbluth et al. Apr 2010 B2
7717934 Kusleika May 2010 B2
7731683 Jang et al. Jun 2010 B2
7736355 Itou et al. Jun 2010 B2
7766049 Miller et al. Aug 2010 B2
7766820 Core Aug 2010 B2
7771358 Moehring et al. Aug 2010 B2
7785286 Magnin et al. Aug 2010 B2
7803136 Schatz Sep 2010 B2
7806906 Don Michael Oct 2010 B2
7815626 McFadden et al. Oct 2010 B1
7827656 Schweikert Nov 2010 B2
7837692 Mulholland et al. Nov 2010 B2
7842055 Pintor et al. Nov 2010 B2
7842065 Belef et al. Nov 2010 B2
7850642 Moll et al. Dec 2010 B2
7850654 Belhe et al. Dec 2010 B2
7854746 Dorn et al. Dec 2010 B2
7867216 Wahr et al. Jan 2011 B2
7879062 Galdonik et al. Feb 2011 B2
7905856 McGuckin, Jr. et al. Mar 2011 B2
7905877 Jimenez et al. Mar 2011 B1
7905891 Self Mar 2011 B2
7909812 Jansen et al. Mar 2011 B2
7927309 Palm Apr 2011 B2
7927347 Hogendijk et al. Apr 2011 B2
7931659 Bose et al. Apr 2011 B2
7938820 Webster et al. May 2011 B2
7967789 Solar et al. Jun 2011 B2
7972294 Nash et al. Jul 2011 B2
7972298 Wallace et al. Jul 2011 B2
7972308 Putz Jul 2011 B2
7988646 Taber Aug 2011 B2
7998104 Chang Aug 2011 B2
8021351 Boldenow et al. Sep 2011 B2
8029533 Bagaoisan et al. Oct 2011 B2
8043279 Hisamatsu et al. Oct 2011 B2
8048032 Root et al. Nov 2011 B2
8052636 Moll et al. Nov 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070694 Galdonik et al. Dec 2011 B2
8084246 Hoon et al. Dec 2011 B2
8092483 Galdonik et al. Jan 2012 B2
8114032 Ferry et al. Feb 2012 B2
8142413 Root et al. Mar 2012 B2
RE43300 Saadat et al. Apr 2012 E
8152782 Jang et al. Apr 2012 B2
8157760 Criado et al. Apr 2012 B2
8172831 Webler, Jr. May 2012 B2
8181324 McFadden et al. May 2012 B2
8211023 Swan et al. Jul 2012 B2
8221348 Hackett et al. Jul 2012 B2
8231600 von Hoffmann Jul 2012 B2
8235968 Tremaglio Aug 2012 B2
8251978 Nash et al. Aug 2012 B2
8252010 Raju et al. Aug 2012 B1
8252014 Fisher Aug 2012 B2
8292850 Root et al. Oct 2012 B2
8308712 Provost et al. Nov 2012 B2
8343089 Chang Jan 2013 B2
8361105 Adams et al. Jan 2013 B2
8366735 Bose et al. Feb 2013 B2
8414516 Chang Apr 2013 B2
8419786 Cottone, Jr. et al. Apr 2013 B2
8425549 Lenker et al. Apr 2013 B2
8460312 Bose et al. Jun 2013 B2
8465456 Stivland Jun 2013 B2
8523801 Nash et al. Sep 2013 B2
8535272 Wang et al. Sep 2013 B2
8540759 Porter Sep 2013 B2
8545552 Garrison et al. Oct 2013 B2
8574245 Garrison et al. Nov 2013 B2
8609426 Silver Dec 2013 B2
8636714 McFerran Jan 2014 B2
8663259 Levine et al. Mar 2014 B2
8682411 Kassab et al. Mar 2014 B2
8690907 Janardhan et al. Apr 2014 B1
8702680 Jimenez et al. Apr 2014 B2
8708954 Webler Apr 2014 B2
8725249 Bar-Yoseph et al. May 2014 B2
8734374 Aklog et al. May 2014 B2
8758325 Webster et al. Jun 2014 B2
8764779 Levine et al. Jul 2014 B2
8764813 Jantzen et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8801670 Drontle et al. Aug 2014 B2
8801749 Adams et al. Aug 2014 B2
8814892 Galdonik et al. Aug 2014 B2
8870805 Chang Oct 2014 B2
8876776 Kassab et al. Nov 2014 B2
8932286 Terry et al. Jan 2015 B2
8932320 Janardhan et al. Jan 2015 B1
RE45380 Root et al. Feb 2015 E
8961533 Stahler et al. Feb 2015 B2
8961549 Conn Feb 2015 B2
8974411 McKinnon Mar 2015 B2
8996095 Anderson et al. Mar 2015 B2
9014786 Carmeli et al. Apr 2015 B2
9023070 Levine et al. May 2015 B2
9034007 Janardhan May 2015 B2
9107691 Fojtik Aug 2015 B2
9119656 Bose et al. Sep 2015 B2
9126018 Garrison Sep 2015 B1
9144383 Zharov Sep 2015 B2
9144662 Di Caprio et al. Sep 2015 B2
RE45760 Root et al. Oct 2015 E
RE45776 Root et al. Oct 2015 E
9199057 Nielsen Dec 2015 B2
9211132 Bowman Dec 2015 B2
9220562 Brannan et al. Dec 2015 B2
9233230 Puhasmagi et al. Jan 2016 B2
9241699 Kume et al. Jan 2016 B1
9259215 Chou et al. Feb 2016 B2
9259228 Cruise et al. Feb 2016 B2
9265512 Garrison et al. Feb 2016 B2
9278201 Rapaport et al. Mar 2016 B2
9282992 Levine et al. Mar 2016 B2
9295817 Chang Mar 2016 B2
9314268 Cahill Apr 2016 B2
9351993 Cruise et al. May 2016 B2
9352123 Zhou et al. May 2016 B2
9370639 Plassman et al. Jun 2016 B2
9375223 Wallace Jun 2016 B2
9381278 Constant et al. Jul 2016 B2
9399118 Kume et al. Jul 2016 B2
RE46116 Root et al. Aug 2016 E
9408916 Cruise et al. Aug 2016 B2
9414819 Fitz et al. Aug 2016 B2
9439791 Vong et al. Sep 2016 B2
9445828 Turjman et al. Sep 2016 B2
9451884 Zharov et al. Sep 2016 B2
9451963 Cruise et al. Sep 2016 B2
9486221 Cruise et al. Nov 2016 B2
9486611 Petersen et al. Nov 2016 B2
9492637 Garrison et al. Nov 2016 B2
9504476 Gulachenski Nov 2016 B2
9510855 Rapaport et al. Dec 2016 B2
9526504 Chang Dec 2016 B2
9526505 Marks et al. Dec 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9546236 Cruise et al. Jan 2017 B2
9561121 Sudin et al. Feb 2017 B2
9561125 Bowman et al. Feb 2017 B2
9561345 Garrison et al. Feb 2017 B2
9597101 Galdonik et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9623228 Ryan et al. Apr 2017 B2
9655633 Leynov et al. May 2017 B2
9655755 Chou et al. May 2017 B2
9655989 Cruise et al. May 2017 B2
9662118 Chang May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662480 Kume et al. May 2017 B2
9669183 Chang Jun 2017 B2
9669191 Chou et al. Jun 2017 B2
9681882 Garrison et al. Jun 2017 B2
9688788 Plotkin et al. Jun 2017 B2
9693789 Garrison et al. Jul 2017 B2
9693852 Lam et al. Jul 2017 B2
9717500 Tieu et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman et al. Sep 2017 B2
9789242 Criado et al. Oct 2017 B2
9803043 Cruise et al. Oct 2017 B2
9820761 Garrison et al. Nov 2017 B2
9827047 Fudaba et al. Nov 2017 B2
9861783 Garrison et al. Jan 2018 B2
9877731 Cruise et al. Jan 2018 B2
9883885 Hendrick et al. Feb 2018 B2
9907880 Cruise et al. Mar 2018 B2
10058339 Galdonik et al. Aug 2018 B2
10124146 Di Caprio et al. Nov 2018 B2
10183146 Yang et al. Jan 2019 B2
10192230 Look et al. Jan 2019 B2
10441301 Vale et al. Oct 2019 B2
10456552 Goyal Oct 2019 B2
10485956 O'Donovan Nov 2019 B2
11065019 Chou et al. Jul 2021 B1
20010014790 Heller et al. Aug 2001 A1
20010027310 Parisi et al. Oct 2001 A1
20010031980 Wensel et al. Oct 2001 A1
20010044598 Parodi Nov 2001 A1
20010044600 Elkins Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010049486 Evans et al. Dec 2001 A1
20010049517 Zadno-Azizi et al. Dec 2001 A1
20010051811 Bonnette et al. Dec 2001 A1
20020016565 Zadno-Azizi et al. Feb 2002 A1
20020026145 Bagaoisan et al. Feb 2002 A1
20020035347 Bagaoisan et al. Mar 2002 A1
20020055747 Cano et al. May 2002 A1
20020062133 Gilson et al. May 2002 A1
20020072705 Vrba et al. Jun 2002 A1
20020087076 Meguro et al. Jul 2002 A1
20020087119 Parodi Jul 2002 A1
20020091407 Zadno-Azizi et al. Jul 2002 A1
20020095174 Tsugita et al. Jul 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020123765 Sepetka et al. Sep 2002 A1
20020128679 Turovskiy et al. Sep 2002 A1
20020133111 Shadduck Sep 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020143362 Macoviak et al. Oct 2002 A1
20020151922 Hogendijk et al. Oct 2002 A1
20020151927 Douk et al. Oct 2002 A1
20020156455 Barbut Oct 2002 A1
20020156460 Ye et al. Oct 2002 A1
20020165571 Hebert et al. Nov 2002 A1
20020165574 Ressemann et al. Nov 2002 A1
20020165598 Wahr et al. Nov 2002 A1
20020169472 Douk et al. Nov 2002 A1
20020173785 Spear et al. Nov 2002 A1
20020173815 Hogendijk et al. Nov 2002 A1
20020177899 Eum et al. Nov 2002 A1
20020183782 Tsugita et al. Dec 2002 A1
20020183783 Shadduck Dec 2002 A1
20030023263 Krolik et al. Jan 2003 A1
20030040762 Dorros et al. Feb 2003 A1
20030050600 Ressemann et al. Mar 2003 A1
20030065353 Horzewski et al. Apr 2003 A1
20030065356 Tsugita et al. Apr 2003 A1
20030069468 Bolling et al. Apr 2003 A1
20030078562 Makower et al. Apr 2003 A1
20030120208 Houser et al. Jun 2003 A1
20030135193 Hilgers et al. Jul 2003 A1
20030135198 Berhow et al. Jul 2003 A1
20030135232 Douk et al. Jul 2003 A1
20030153942 Wang et al. Aug 2003 A1
20030186203 Aboud Oct 2003 A1
20030191492 Gellman et al. Oct 2003 A1
20030212304 Lattouf Nov 2003 A1
20030212384 Hayden Nov 2003 A1
20030233038 Hassett Dec 2003 A1
20040006344 Nguyen et al. Jan 2004 A1
20040006365 Brady et al. Jan 2004 A1
20040015151 Chambers Jan 2004 A1
20040019322 Hoffmann Jan 2004 A1
20040059243 Flores et al. Mar 2004 A1
20040116878 Byrd et al. Jun 2004 A1
20040122360 Waldhauser et al. Jun 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138608 Barbut et al. Jul 2004 A1
20040153049 Hewitt et al. Aug 2004 A1
20040153118 Clubb et al. Aug 2004 A1
20040193177 Houghton et al. Sep 2004 A1
20040210194 Bonnette et al. Oct 2004 A1
20040220611 Ogle Nov 2004 A1
20040230285 Gifford, III et al. Nov 2004 A1
20040236215 Mihara et al. Nov 2004 A1
20040243102 Berg et al. Dec 2004 A1
20040254602 Lehe et al. Dec 2004 A1
20050004523 Osborne et al. Jan 2005 A1
20050004553 Douk Jan 2005 A1
20050021075 Bonnette et al. Jan 2005 A1
20050021152 Ogle et al. Jan 2005 A1
20050027236 Douk Feb 2005 A1
20050049574 Petrick et al. Mar 2005 A1
20050059957 Campbell et al. Mar 2005 A1
20050065467 Pudelko et al. Mar 2005 A1
20050065498 McFerran Mar 2005 A1
20050085847 Galdonik et al. Apr 2005 A1
20050090802 Connors et al. Apr 2005 A1
20050103332 Gingles et al. May 2005 A1
20050131453 Parodi Jun 2005 A1
20050154344 Chang Jul 2005 A1
20050154349 Renz et al. Jul 2005 A1
20050182386 Aggerholm Aug 2005 A1
20050209559 Thornton et al. Sep 2005 A1
20050209631 Galdonik et al. Sep 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050209675 Ton et al. Sep 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050273051 Coppi Dec 2005 A1
20050277976 Galdonik et al. Dec 2005 A1
20060020165 Adams Jan 2006 A1
20060030835 Sherman et al. Feb 2006 A1
20060030876 Peacock et al. Feb 2006 A1
20060047301 Ogle Mar 2006 A1
20060058836 Bose et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060064036 Osborne et al. Mar 2006 A1
20060079787 Whiting et al. Apr 2006 A1
20060089618 McFerran et al. Apr 2006 A1
20060095062 Stephens May 2006 A1
20060100530 Kliot et al. May 2006 A1
20060129091 Bonnette et al. Jun 2006 A1
20060135961 Rosenman et al. Jun 2006 A1
20060173440 Lamson et al. Aug 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060200047 Galdonik et al. Sep 2006 A1
20060200191 Zadno-Azizi Sep 2006 A1
20060217664 Hattler et al. Sep 2006 A1
20060247755 Pal et al. Nov 2006 A1
20060258987 Lentz et al. Nov 2006 A1
20060259063 Bates et al. Nov 2006 A1
20060264759 Moehring et al. Nov 2006 A1
20060271098 Peacock Nov 2006 A1
20070016132 Oepen et al. Jan 2007 A1
20070021778 Carly Jan 2007 A1
20070043333 Kampa et al. Feb 2007 A1
20070060888 Goff et al. Mar 2007 A1
20070060908 Webster et al. Mar 2007 A1
20070060911 Webster et al. Mar 2007 A1
20070060944 Boldenow et al. Mar 2007 A1
20070073264 Stedman et al. Mar 2007 A1
20070106211 Provost-Tine et al. May 2007 A1
20070135733 Soukup et al. Jun 2007 A1
20070173784 Johansson et al. Jul 2007 A1
20070185501 Martin et al. Aug 2007 A1
20070185521 Bui et al. Aug 2007 A1
20070185522 Davies et al. Aug 2007 A1
20070197956 Le et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070198049 Barbut Aug 2007 A1
20070208302 Webster et al. Sep 2007 A1
20070227543 Peichel Oct 2007 A1
20070250040 Provost et al. Oct 2007 A1
20070250096 Yamane et al. Oct 2007 A1
20070260115 Brock et al. Nov 2007 A1
20070260219 Root et al. Nov 2007 A1
20080027379 Wilkins Jan 2008 A1
20080033525 Shaked et al. Feb 2008 A1
20080058839 Nobles et al. Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080082109 Moll et al. Apr 2008 A1
20080086110 Galdonik et al. Apr 2008 A1
20080097251 Babaev Apr 2008 A1
20080109088 Galdonik et al. May 2008 A1
20080119890 Adams et al. May 2008 A1
20080140010 Kennedy et al. Jun 2008 A1
20080167678 Morsi Jul 2008 A1
20080172066 Galdonik et al. Jul 2008 A9
20080177245 Mesallum Jul 2008 A1
20080183128 Morriss et al. Jul 2008 A1
20080188888 Adams et al. Aug 2008 A1
20080195140 Myla et al. Aug 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080234723 Buiser et al. Sep 2008 A1
20080243222 Schafersman et al. Oct 2008 A1
20080262350 Unger Oct 2008 A1
20080262472 Lunn et al. Oct 2008 A1
20080294111 Tal et al. Nov 2008 A1
20080312639 Weber Dec 2008 A1
20090018455 Chang Jan 2009 A1
20090018525 Waite et al. Jan 2009 A1
20090024072 Criado et al. Jan 2009 A1
20090024089 Levine et al. Jan 2009 A1
20090030400 Bose et al. Jan 2009 A1
20090082800 Janardhan Mar 2009 A1
20090124956 Swetlin et al. May 2009 A1
20090165881 Tegg et al. Jul 2009 A1
20090198172 Garrison et al. Aug 2009 A1
20090209857 Secretain et al. Aug 2009 A1
20090227992 Nir et al. Sep 2009 A1
20090234321 Shapland et al. Sep 2009 A1
20090247987 Chevalier, Jr. et al. Oct 2009 A1
20090254166 Chou et al. Oct 2009 A1
20090264865 Kawai Oct 2009 A1
20090270800 Spurchise et al. Oct 2009 A1
20090281379 Binmoeller et al. Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20090312699 Pudelko et al. Dec 2009 A1
20100004607 Wilson et al. Jan 2010 A1
20100022948 Wilson et al. Jan 2010 A1
20100030141 Chermoni Feb 2010 A1
20100042118 Garrison et al. Feb 2010 A1
20100049168 Parker et al. Feb 2010 A1
20100057051 Howat et al. Mar 2010 A1
20100063479 Merdan et al. Mar 2010 A1
20100063480 Shireman Mar 2010 A1
20100094330 Barbut Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100145308 Layman et al. Jun 2010 A1
20100185216 Garrison et al. Jul 2010 A1
20100204672 Lockhart et al. Aug 2010 A1
20100204684 Garrison et al. Aug 2010 A1
20100211050 Luther Aug 2010 A1
20100217235 Thorstenson et al. Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100228269 Garrison et al. Sep 2010 A1
20100256600 Ferrera Oct 2010 A1
20100268029 Phan et al. Oct 2010 A1
20100312141 Keast et al. Dec 2010 A1
20100318097 Ferrera et al. Dec 2010 A1
20110009875 Grandfield et al. Jan 2011 A1
20110015482 Carrillo, Jr. Jan 2011 A1
20110034986 Chou et al. Feb 2011 A1
20110082373 Gurley et al. Apr 2011 A1
20110087147 Garrison et al. Apr 2011 A1
20110106200 Ziegler May 2011 A1
20110112567 Lenker et al. May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152760 Parker Jun 2011 A1
20110172678 Behl et al. Jul 2011 A1
20110172700 Bose et al. Jul 2011 A1
20110230859 Galdonik et al. Sep 2011 A1
20110238041 Lim et al. Sep 2011 A1
20110264133 Hanlon et al. Oct 2011 A1
20120040858 Ford et al. Feb 2012 A1
20120065479 Lahiji et al. Mar 2012 A1
20120065490 Zharov et al. Mar 2012 A1
20120071838 Fojtik Mar 2012 A1
20120071856 Goldfarb et al. Mar 2012 A1
20120078140 Nita Mar 2012 A1
20120095485 Cully et al. Apr 2012 A1
20120101561 Porter Apr 2012 A1
20120109044 Santamore et al. May 2012 A1
20120116350 Strauss et al. May 2012 A1
20120123466 Porter et al. May 2012 A1
20120148175 Wesselmann Jun 2012 A1
20120150147 Leynov et al. Jun 2012 A1
20120179097 Cully et al. Jul 2012 A1
20120253313 Galdonik et al. Oct 2012 A1
20120271281 Schertiger Oct 2012 A1
20120310212 Fischell et al. Dec 2012 A1
20120330196 Nita Dec 2012 A1
20130006225 Cucin Jan 2013 A1
20130018318 Ravichandran et al. Jan 2013 A1
20130035628 Garrison et al. Feb 2013 A1
20130046285 Griffin et al. Feb 2013 A1
20130053792 Fischell et al. Feb 2013 A1
20130116701 Wang et al. May 2013 A1
20130158507 Brown Jun 2013 A1
20130158578 Ghodke et al. Jun 2013 A1
20130165873 Morriss et al. Jun 2013 A1
20130184735 Fischell et al. Jul 2013 A1
20130197621 Ryan et al. Aug 2013 A1
20130226276 Newell et al. Aug 2013 A1
20130274783 Wynberg Oct 2013 A1
20130281788 Garrison Oct 2013 A1
20140018773 Wang et al. Jan 2014 A1
20140025004 Falk et al. Jan 2014 A1
20140025043 Wang et al. Jan 2014 A1
20140039461 Anderson et al. Feb 2014 A1
20140046297 Shimada et al. Feb 2014 A1
20140088510 Nimkar et al. Mar 2014 A1
20140114287 Beasley et al. Apr 2014 A1
20140155783 Starksen et al. Jun 2014 A1
20140155908 Rosenbluth et al. Jun 2014 A1
20140155932 Weishaupt et al. Jun 2014 A1
20140180246 Comerota et al. Jun 2014 A1
20140207043 Anand et al. Jul 2014 A1
20140228808 Webster et al. Aug 2014 A1
20140236120 Tsai et al. Aug 2014 A1
20140249508 Wang et al. Sep 2014 A1
20140257018 Farnan Sep 2014 A1
20140257186 Kerr Sep 2014 A1
20140273920 Smith Sep 2014 A1
20140276618 Di Caprio et al. Sep 2014 A1
20140276920 Hendrick et al. Sep 2014 A1
20140276923 Miller Sep 2014 A1
20140288525 Fudaba et al. Sep 2014 A1
20140296769 Hyde et al. Oct 2014 A1
20140296868 Garrison et al. Oct 2014 A1
20140296889 Avneri et al. Oct 2014 A1
20140343537 Eversull et al. Nov 2014 A1
20140358123 Ueda et al. Dec 2014 A1
20140358178 Hewitt et al. Dec 2014 A1
20140371709 Allen et al. Dec 2014 A1
20150025562 Dinh et al. Jan 2015 A1
20150080939 Adams et al. Mar 2015 A1
20150105729 Valeti et al. Apr 2015 A1
20150119859 Cajamarca et al. Apr 2015 A1
20150126861 Gambhir et al. May 2015 A1
20150133978 Paul, Jr. May 2015 A1
20150151090 Sutton et al. Jun 2015 A1
20150165160 Thungana et al. Jun 2015 A1
20150173782 Garrison et al. Jun 2015 A1
20150174368 Garrison et al. Jun 2015 A1
20150196210 McCaffrey et al. Jul 2015 A1
20150245848 Shimon Sep 2015 A1
20150265802 Fukuoka et al. Sep 2015 A1
20150282821 Look et al. Oct 2015 A1
20150327843 Garrison Nov 2015 A1
20150327919 Clopp et al. Nov 2015 A1
20150335857 Ishikawa Nov 2015 A1
20150352330 Wasdyke et al. Dec 2015 A1
20160008025 Gupta et al. Jan 2016 A1
20160008572 Di Caprio et al. Jan 2016 A1
20160015935 Chan et al. Jan 2016 A1
20160022964 Goyal Jan 2016 A1
20160058459 Bowman Mar 2016 A1
20160066931 Kugler et al. Mar 2016 A1
20160081825 Sudin et al. Mar 2016 A1
20160100819 Tieu Apr 2016 A1
20160121081 Iwano et al. May 2016 A1
20160128688 Garrison et al. May 2016 A1
20160129221 Haverkost et al. May 2016 A1
20160135829 Holochwost et al. May 2016 A1
20160144157 Gulachenski et al. May 2016 A1
20160166265 Nita Jun 2016 A1
20160166266 Nita Jun 2016 A1
20160199204 Pung et al. Jul 2016 A1
20160199620 Pokorney et al. Jul 2016 A1
20160206322 Fitz et al. Jul 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20160242764 Garrison et al. Aug 2016 A1
20160242893 Joshi et al. Aug 2016 A1
20160243157 Cruise et al. Aug 2016 A1
20160256611 Fitz Sep 2016 A1
20160270806 Wallace Sep 2016 A1
20160271315 Chang Sep 2016 A1
20160296690 Kume et al. Oct 2016 A1
20160311990 Cruise et al. Oct 2016 A1
20160317156 Fitz et al. Nov 2016 A1
20160317288 Rogers et al. Nov 2016 A1
20160345904 Bowman Dec 2016 A1
20160346502 Fuller et al. Dec 2016 A1
20160346508 Williams et al. Dec 2016 A1
20160346509 Anderson et al. Dec 2016 A1
20160361180 Vong et al. Dec 2016 A1
20160361459 Baldwin Dec 2016 A1
20160367272 Garrison et al. Dec 2016 A1
20160367274 Wallace Dec 2016 A1
20160367275 Wallace Dec 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007277 Drapeau et al. Jan 2017 A1
20170020540 Chou et al. Jan 2017 A1
20170027604 Wallace Feb 2017 A1
20170028170 Ho Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035446 Rapaport et al. Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170056061 Ogle et al. Mar 2017 A1
20170072165 Lim et al. Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079817 Sepetka et al. Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170087340 Peralta et al. Mar 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170143938 Ogle et al. May 2017 A1
20170147765 Mehta May 2017 A1
20170164964 Galdonik et al. Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170209260 Garrison et al. Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231647 Saunders et al. Aug 2017 A1
20170246014 Rapaport et al. Aug 2017 A1
20170252043 Fuller et al. Sep 2017 A1
20170265869 Cibulski et al. Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170274180 Garrison et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281204 Garrison et al. Oct 2017 A1
20170283536 Cruise et al. Oct 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20170354421 Maguire et al. Dec 2017 A1
20170354523 Chou et al. Dec 2017 A1
20170354803 Kume et al. Dec 2017 A1
20170360450 Tompkins et al. Dec 2017 A1
20170361072 Chou et al. Dec 2017 A1
20170367713 Greene, Jr. et al. Dec 2017 A1
20170367857 Bennett et al. Dec 2017 A1
20170368296 Chang Dec 2017 A1
20170368309 Garrison et al. Dec 2017 A1
20180008294 Garrison et al. Jan 2018 A1
20180008439 Tieu et al. Jan 2018 A9
20180014840 Panian Jan 2018 A1
20180028205 Chou et al. Feb 2018 A1
20180028209 Sudin et al. Feb 2018 A1
20180036155 Tieu et al. Feb 2018 A1
20180055516 Baldwin et al. Mar 2018 A1
20180064453 Garrison et al. Mar 2018 A1
20180116684 Garrison et al. May 2018 A1
20180133436 Garrison et al. May 2018 A1
20180242978 Chou et al. Aug 2018 A1
20190008534 Garrison et al. Jan 2019 A1
20190046218 Garrison et al. Feb 2019 A1
20190366042 Garrison et al. Dec 2019 A1
20190366043 Garrison et al. Dec 2019 A1
20200016369 Garrison et al. Jan 2020 A1
20200046939 Garrison et al. Feb 2020 A1
20200046940 Garrison et al. Feb 2020 A1
20200060722 O'Connell et al. Feb 2020 A1
20200164178 Garrison et al. May 2020 A1
20200187965 Garrison et al. Jun 2020 A1
20200337716 Garrison et al. Oct 2020 A1
20200345981 Garrison et al. Nov 2020 A1
20210045758 Garrison et al. Feb 2021 A1
20210052296 Garrison Feb 2021 A1
20210069467 Garrison et al. Mar 2021 A1
20210138193 Garrison et al. May 2021 A1
20210138194 Garrison et al. May 2021 A1
20210212707 Chou et al. Jul 2021 A1
20220047285 Chou et al. Feb 2022 A1
20220338888 Chou et al. Oct 2022 A1
Foreign Referenced Citations (60)
Number Date Country
101121055 Feb 2008 CN
101588835 Nov 2009 CN
103260689 Aug 2013 CN
103648574 Mar 2014 CN
104394785 Mar 2015 CN
104739486 Jul 2015 CN
105920720 Sep 2016 CN
102006039236 Feb 2008 DE
117940 Sep 1984 EP
0427429 May 1991 EP
1226795 Jul 2002 EP
1440663 Jul 2004 EP
1639951 Mar 2006 EP
2069528 Mar 2013 EP
2020557 Nov 1979 GB
3026200 Jul 1996 JP
H11-146883 Jun 1999 JP
2002291756 Oct 2002 JP
2003-521286 Jul 2003 JP
2003-522560 Jul 2003 JP
2005-500138 Jan 2005 JP
2005-523123 Aug 2005 JP
2008517652 May 2008 JP
3142466 Jun 2008 JP
2014-138756 Jul 2014 JP
WO-9317750 Sep 1993 WO
WO-9402194 Feb 1994 WO
WO-9505209 Feb 1995 WO
WO-9838930 Sep 1998 WO
WO-9945835 Sep 1999 WO
WO-0016705 Mar 2000 WO
WO-0032266 Jun 2000 WO
WO-0076390 Dec 2000 WO
WO-0115767 Mar 2001 WO
WO-0158365 Aug 2001 WO
WO-0232495 Apr 2002 WO
WO-02055146 Jul 2002 WO
WO-02085092 Oct 2002 WO
WO-03018085 Mar 2003 WO
WO-03090831 Nov 2003 WO
WO-2004006803 Jan 2004 WO
WO-2005051206 Jun 2005 WO
WO-2005084130 Sep 2005 WO
WO-2006111944 Oct 2006 WO
WO-2006127929 Nov 2006 WO
WO-2006132434 Dec 2006 WO
WO-2008006111 Jan 2008 WO
WO-2008144587 Nov 2008 WO
WO-2009012473 Jan 2009 WO
WO-2009099764 Aug 2009 WO
WO-2009100210 Aug 2009 WO
WO-2010075565 Jul 2010 WO
WO-2010083167 Jul 2010 WO
WO-2012035633 Mar 2012 WO
WO-2012047803 Apr 2012 WO
WO-2014008489 Jan 2014 WO
WO-2014203336 Dec 2014 WO
WO-2015042368 Mar 2015 WO
WO-2015100178 Jul 2015 WO
WO-2015157330 Oct 2015 WO
Non-Patent Literature Citations (136)
Entry
U.S. Appl. No. 15/699,401, filed Sep. 8, 2017, US 2017-0368309.
U.S. Appl. No. 15/727,373, filed Oct. 6, 2017, US 2018-0028205.
U.S. Appl. No. 15/747,089, filed Jan. 23, 2018, US 2018-0242978.
U.S. Appl. No. 16/530,845, filed Aug. 2, 2019, US 2020-0023160.
U.S. Appl. No. 16/543,215, filed Aug. 16, 2019, US 2019-0366042.
U.S. Appl. No. 16/543,226, filed Aug. 16, 2019, US 2019-0366043.
U.S. Appl. No. 16/584,220, filed Sep. 26, 2019, US 2020-0016369.
U.S. Appl. No. 16/596,531, filed Oct. 8, 2019, US 2020-0046939.
U.S. Appl. No. 17/152,575, filed Jan. 19, 2021, US 2021-0138193.
U.S. Appl. No. 13/921,165, filed Jun. 18, 2013, US 2013-0281788.
U.S. Appl. No. 15/866,012, filed Jan. 9, 2018, US 2018-0193042.
U.S. Appl. No. 15/875,214, filed Jan. 19, 2018, US 2018-0361114.
U.S. Appl. No. 15/875,342, filed Jan. 19, 2018, US 2018-0207399.
U.S. Appl. No. 16/117,741, filed Aug. 30, 2018, US 2019-0008534.
U.S. Appl. No. 16/117,753, filed Aug. 30, 2018, US 2019-0046218.
PCT/US2019/032694, May 16, 2019, WO 2019/222518.
Paullus WS, Pait TG, Rhoton Al Jr. Microsurgical exposure of the petrous portion of the carotid artery. J Neurosurg. 1977;47(5):713-726. (Year: 1977).
Seidel, A. et al. (2005). “Relationship between the diameter of great saphenous vein and body mass index,” J Vasc Bras, vol. 4, No. 3, p. 265-269.
“2007 International Stroke Conference: Abstracts.” Stroke, vol. 38, No. 2, 2007, pp. 454-607. Web. Downloaded Jun. 13, 2017.
“2012 Buyer's Guide: Microcatheters.” Endovascular Today, 2012, pp. 48-51.
“2017 Buyer's Guide: Microcatheters.” Endovascular Today, http://evtoday.com/buyers-guide/chart.asp?id=25. Accessed on Oct. 10, 2017. 11 pages.
“Asahi Fubuki Catheter Dilator Kit.” Asahi-lntecc USA Medical. 2017. Web. Accessed Oct. 2, 2017. 3 pages, www.asahi-inteccusa-medical.com/medical-product/fubuki-dilator-kit/. Accessed Oct. 2, 2017.
Farooq, Vasim et al. “Forward and Back Aspiration during ST-Elevation Myocardial Infarction: a Feasibility Study.” EuroIntervention, vol. 11, No. 14, 2016, pp. 1639-1648.
Farooq, Vasim et al. “The Use of A Guide Catheter Extension System as an Aid During Transradial Percutaneous Coronary Intervention of Coronary Artery Bypass Grafts.” Catheterization and Cardiovascular Interventions, vol. 78, No. 6, 2011, pp. 847-863.
Feldman, “Transcatheter Aspiration of a Thrombus in an Aortocoronary Saphenous Vein Graft,” American Journal of Cardiology, 60(4):379-380. (1987).
Guidezilla Guide Extension Catheter, Boston Scientific 510k Submission, Feb. 19, 2013, 5 pages. Web. Accessed Oct. 23, 2017.
Heart and Stroke Foundation of Canada. “Vacuum cleaner sucks up strokes.” ScienceDaily, Jun. 8, 2010, 4 pages, www.sciencedaily.com/releases/2010/06/100608162240.htm.
Kopeck, Rachel. “Penumbra, Inc. Launches 5MAX™ ACE—The Newest Clot Extraction Device to Treat Acute Ischemic Stroke Patients.” Penumbra Inc., Jul. 8, 2013, 3 pages, http://www.penumbrainc.com/news/penumbra-inc-launches-5max-ace-the-newest-clot-extraction-device-to-treat-acute-ischemic-stroke-patients/.
Merit Medical Systems Acquired Distal Access's SPINR Platform, Jul. 15, 2015, Digital Access, LLC; Merit Medical Systems, 5 pages. Web. Accessed Oct. 23, 2017.
Patel, Tejas et al. (2014) “Balloon-Assisted Tracking: A Must-Know Technique to Overcome Difficult Anatomy During Transradial Approach,” Catheter Cardiovasc. Interv., 83(2):211-220.
Pena, Carlos. “Letter to Sequent Medical Inc Re: K150894, Trade/Device Name: VIA™ 21 Microcatheter.” Department of Health & Human Services, Aug. 28, 2015, 14 pages.
Penumbra, Inc., “Penumbra, Inc. Completes Pivotal Stroke Trial of Intracranial Revascularization,” Press Release, (2007). Web. Accessed Jun. 14, 2017. 2 pages.
Penumbra, Inc., “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease,” Stroke 2009, 40:2761-2768. Web. Downloaded Jun. 15, 2017.
Reeder et al., “Aspiration Thrombectomy for Removal of Coronary Thrombus,” American Journal of Cardiology. (Jul. 1, 1992) 70:107-110 (Abstract only).
Request for Ex Parte Reexamination Transmittal Form and Request for Ex Parte Reexamination pursuant to 37 CFR 1.150 of U.S. Pat. No. 9,820,761 issued Nov. 21, 2017. Request filed May 11, 2018 and assigned U.S. Appl. No. 90/014,136. 35 pages.
Simon et al., Exploring the efficacy of cyclic vs. static aspiration in a cerebral thrombectomy model: an initial proof of concept study, J. Neuro Intervent Surg 2014, 6, pp. 677-683. Web. Downloaded Oct. 18, 2017.
Simon et al., Hydrodynamic comparison of the Penumbra system and commonly available syringes in forced-suction thrombectomy, J. Neuro Intervent Surg 2014, 6, pp. 205-211. Web. Downloaded Oct. 18, 2017.
Spiotta et al., Evolution of thrombectomy approaches and devices for acute stroke: a technical review, J. Neuro Intervent Surg 2015, 7, pp. 2-7. Web. Downloaded Oct. 18, 2017.
Stys, Adam T. et al. “A Novel Application of GuideLiner Catheter for Thrombectomy in Acute Myocardial Infarction: A Case Series.” Journal of Invasive Cardiology, vol. 25, No. 11, 2013, pp. E254-E259. 6 pages, (http://www.invasivecardiology.com/issue/4284).
Turk, Aquilla S, et al. (2014) “Initial clinical experience with the ADAPT technique: A direct aspiration first pass technique for stroke thrombectomy.” J NeuroIntervent Surg 2014;6:231-237. doi:10.1136/neurintsurg-2013-010713. Web. Accessed Sep. 26, 2018.
Vijaywargiya et al. “Anatomical study of petrous and cavernous parts of internal carotid artery”. Anatomy and Cell Biology 2017;50: 163-170. (Year: 2017).
Webb et al., “Retrieval and Analysis of Particulate Debris After Saphenous Vein Graft Intervention,” Journal of the American College of Cardiology, 34(2);468-475 (1999).
Yoo et al., “The Penumbra Stroke System: a technical review.” Journal of NeuroInterventional Surgery. 4:199-205 (2012). Web. Downloaded Jun. 15, 2017.
Zuckerman, Bram. “Letter to Cathera Inc: Re K151638, Trade/Device Name: Phenom™ Catheters.” Department of Health & Human Services, Nov. 13, 2015, 6 pages.
U.S. Appl. No. 16/319,038, filed Jul. 21, 2017, US 2021-0330332.
U.S. Appl. No. 16/775,105, filed Jan. 28, 2020, US 2020-0164178.
U.S. Appl. No. 17/748,523, filed May 19, 2022, US 2022-0280753.
PCT/US21/35387, Jun. 2, 2021, WO 2021/247660.
PCT/US21/54280, Oct. 8, 2021, WO 2022/076893.
Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.
Alexandrescu et al. (2006) “Filter-protected carotid stenting via a minimal cervical access with transitory aspirated reversed flow during initial passage of the target lesion.” J. Endovasc. Ther. 13(2):196-204.
Alvarez et al. (2008). “Transcervical carotid stenting with flow reversal is safe in octogenarians: A preliminary safety study” J. Vase. Surg. 47:96-100.
Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275, (2003).
Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.
Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European CAST I Study” J. Endovasc. Surg. 6:155-159.
Bergeron et al. (2008). MEET Presentation, Cannes, French Riviera “Why I do not use routine femoral access for CAS.” 12 pages.
Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.
Bourekas, E. C., A. P. Slivka, et al. (2004). “Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.” Neurosurgery 54(1): 39-44; discussion 44-6.
Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).
Chang, M.D., “Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.
Cohen et al., “A reappraisal of the common carotid artery as an access site in interventional procedures for acute stroke therapies”, Case Reports, Journal of Clinical Neuroscience 19 (2012) pp. 323-326.
Coppi et al. (2005). “PRIAMUS Proximal flow blockage cerebral protection during carotid stenting: Results from a multicenter Italian regiStry” J. Cardiovasc. Surg. 46:219-227.
Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.
Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.
Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.
Criado, et al. (2007). “Transcervical carotid stenting with carotid artery flow reversal: 3-year follow-up of 103 stents.” J Vasc Surg 46(5): 864-9.
Criado, F.J., et al. (2000). “Access strategies for carotid artery intervention.” J Invasive Cardiol, 2000. 12(1): p. 61-68.
Criado, M.D., et al. (2004). “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient.” Journal of Vascular Surgery, 40(1):92-7.
Delgado Almandoz, Josser E., et al. “Comparison of clinical outcomes in patients with acute ischemic strokes treated with mechanical thrombectomy using either Solumbra or ADAPT techniques.” Journal of NeuroInterventional Surgery, vol. 8, 2016, pp. 1123-1128.
Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.
Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.
Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. lyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.
Feldtman, R. W., C. J. Buckley, et al. (2006). “How I do it: cervical access for carotid artery stenting.” Am J Surg 192(6): 779-781.
Fiorella, D., M. Kelly, et al. (2008). “Endovascular Treatment of Cerebral Aneurysms.” Endovascular Today Jun. 2008. pp. 53-64.
Frazee, J. G. and X. Luo (1999). “Retrograde transvenous perfusion.” Crit Care Clin 15(4): 777-88, vii.
Frazee, J. G., X. Luo, et al. (1998). “Retrograde transvenous neuroperfusion: a back door treatment for stroke.” Stroke 29(9): 1912-6.
Friedrich, Benjamin, et al. “Distance to Thrombus in Acute Middle Cerebral Artery Occlusion.” Stroke, vol. 46, No. 3, 2015, pp. 692-696.
Goldstein “Acute Ischemic Stroke Treatment in 2007” Circ 116:1504-1514 (2007).
Goyal, M. et al. (Mar. 12, 2015, e-published Feb. 11, 2015). “Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke.” N Engl J Med, 372(11):1019-1030.
Gray et al. (2007) “The CAPTURE registry: Results of carotid stenting with embolic protection in the post approval setting” Cath. Cardovasc. Interven. 69:341-348.
Henry, et al. (1999). “Carotid Stenting With Cerebral Protection: First Clinical Experience Using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.
Hoffer et al. “Percutaneous Arterial Closure Devices” J. Vasc. Interv. Radiol. 14:865-885 (2003).
Howell, M., K. Doughtery, et al. (2002). “Percutaneous repair of abdominal aortic aneurysms using the AneuRx stent graft and the percutaneous vascular surgery device.” Catheter Cardiovasc Interv 55(3): 281-7.
Jankowitz, Brian, et al. “Manual Aspiration Thrombectomy Adjunctive Endovascular Recanalization Technique in Acute Stroke Interventions.” Stroke, vol. 43, No. 5, 2012, pp. 1408-1411.
Koebbe, C. J., E. Veznedaroglu, et al. (2006). “Endovascular management of intracranial aneurysms: current experience and future advances.” Neurosurgery 59(5 Suppl 3): S93-102; discussion S3-13.
Lin et al. (2005). “Protected carotid artery stenting and angioplasty via transfemoral versus transcervical approaches.” Vasc. Endovasc. Surg. 39(6):499-503.
Lo et al. (2005). “Advantages and indications of transcervical carotid artery stenting with carotid flow reversal.” J. Cardovasc. Surg (Torino). 46(3):229-239.
Luebke, T et al. (2007).“Meta-analysis of randomized trials comparing carotid endarterectomy and endovascular treatment” Eur. J. Vasc. Endovasc. Surg. 34:470-479.
MacDonald, S. (2006) “Is there any evidence that cerebral protection is beneficial?” J. Cardiovasc. Surg. 47:127-36.
Mas et al. (2006). “Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis” NEJM 355:1660-71.
Matas et al. (2007). “Transcervical carotid stenting with flow reversal protection: Experience in high-risk patients” J. Vasc. Surg. 46:49-54.
Mokin, Maxim, et al. “Primary stentriever versus combined stentriever plus aspiration thrombectomy approaches: in vitro stroke model comparison.” Journal of NeuroInterventional Surgery, vol. 7, 2015, pp. 453-457.
Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages.
Nesbit, G. M., G. Luh, et al. (2004). “New and future endovascular treatment strategies for acute ischemic stroke.” J Vasc Interv Radiol 15(1 Pt 2): S103-10.
Nii, K., K. Kazekawa, et al. (2006). “Direct carotid puncture for the endovascular treatment of anterior circulation aneurysms.” AJNR Am J Neuroradiol 27(7): 1502-4.
Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).
Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.
Parodi (2005). “Is flow reversal the best method of protection during carotid stenting?” J Endovasc. Ther. 12:166-170.
Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.
Parodi, J. C., L. M. Ferreira, et al. (2005). “Cerebral protection during carotid stenting using flow reversal.” J Vasc Surg 41(3): 416-22.
Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.
Pipinos et al. (2005). “Transcervical approach with protective flow reversal for carotid angioplasty and stenting” J. Endovasc. Ther. 12:446-453.
Pipinos et al. (2006). “Transcervical carotid stenting with flow reversal for neuroprotection: Technique, results, advantages, and limitations” 14(5):245-255.
Powers, W.J., et al. (2015, e-published online before print Jun. 29, 2015). “2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association Powers et al. on behalf of the American Heart Association Stroke Council Stroke.” Stroke. 46:3020-3035.
Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.
Reimers et al. (2005). “Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: Results froma prospective multicenter registry” J. Endovasc. Ther. 12:156-165.
Ribo, et al. (2006). “Transcranial doppler monitoring of transcervical carotid stenting with flow reversal protection: a novel carotid revascularization technique” 27:2846-2849. (originally published online Sep. 28, 2006).
Ribo, M., C. Molina, et al. (2008). “Buying Time for Recanalization in Acute Stroke: Arterial Blood Infusion Beyond the Occluding Clot as a Neuroprotective Strategy.” J Neuroimaging. 4 pages.
Ross, I. B. and G. D. Luzardo (2006). “Direct access to the carotid circulation by cut down for endovascular neuro-interventions.” Surg Neurol 65(2): 207-11; discussion 211.
Saver, J.L. et al. (Jun. 11, 2015, e-published Apr. 17, 2015). “Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke.” N Engl J Med, 372(24):2285-2295.
Spinnaker® Elite™ Flow Directed Catheters Go with the Flow. Indications for Use. 2 pages. Web. Aug. 27, 2019.
Spinnaker® Elite™ Flow Directed Catheters Go with the Flow. Promotional Brochure. 1 page. Web. Aug. 27, 2019.
Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417.
Stejskal, et al. “Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy”, Acta Neurochir, 2007, 149:681-689.
Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection” AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.
“Trevo ProVue Retriever.” Stryker Trevo® ProVue™ Retrieval System (bu Concentric Medical®). (2016) Web. Apr. 13, 2018. 2 pages.
U.S. Appl. No. 16/414,532, filed May 16, 2019, US 2019-0351182.
U.S. Appl. No. 16/584,351, filed Sep. 26, 2019, US 2020-0038628.
U.S. Appl. No. 16/596,535, filed Oct. 8, 2019, US 2020-0046940.
U.S. Appl. No. 16/775,105, filed Jan. 28, 2020, US 2020-00164178.
U.S. Appl. No. 16/890,962, filed Jun. 2, 2020, US 2020-0289136.
U.S. Appl. No. 16/925,708, filed Jul. 10, 2020, US 2020-0337716.
U.S. Appl. No. 17/011,448, filed Sep. 3, 2020, US 2021-0052296.
U.S. Appl. No. 17/089,495, filed Nov. 4, 2020, US 2021-0045758.
U.S. Appl. No. 17/093,401, filed Nov. 9, 2020, US 2021-0069467.
U.S. Appl. No. 17/152,581, filed Jan. 19, 2021, US 2021-0138194.
U.S. Appl. No. 17/319,943, filed May 13, 2021, US 2021-0259718.
U.S. Appl. No. 17/481,639, filed Sep. 22, 2021, US 2022-0175565.
U.S. Appl. No. 17/497,713, filed Oct. 8, 2021, US 2022-0111177.
U.S. Appl. No. 17/516,540, filed Nov. 1, 2021, US 2022-0047285.
U.S. Appl. No. 17/545,885, filed Dec. 8, 2021, US 2022-0096103.
U.S. Appl. No. 17/849,379, filed Jun. 24, 2022, US 2022-0313292.
U.S. Appl. No. 17/859,955, filed Jul. 7, 2022, US 2022-0338888.
U.S. Appl. No. 17/883,295, filed Aug. 8, 2022, US 2022-0370767.
U.S. Appl. No. 17/883,430, filed Aug. 8, 2022, US 2022-0370761.
PCT/US21/54280, filed Oct. 8, 2021, WO 2022/076893.
Related Publications (1)
Number Date Country
20200215306 A1 Jul 2020 US
Provisional Applications (2)
Number Date Country
62142637 Apr 2015 US
62111841 Feb 2015 US
Continuations (4)
Number Date Country
Parent 16543215 Aug 2019 US
Child 16821804 US
Parent 15856979 Dec 2017 US
Child 16543215 US
Parent 15805673 Nov 2017 US
Child 15856979 US
Parent 15015799 Feb 2016 US
Child 15805673 US